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Arsenic is a well-studied human carcinogen. The mechanism by which arsenic induces 
cancer, however, is not fully understood. It is known that as a general stress inducer, arsenic can 
activate kinases, such as mitogen-activated protein kinases, leading to over activation of 
transcription factors. These transcription factors, including AP-1, NF-κB and Myc, are known to 
regulate the expression of early response genes, and likely to regulate miRNAs. The expression 
of miRNAs is often altered in cancer and other proliferative disorders. It is highly probable that 
miRNAs whose expressions are altered by arsenic will play a significant role in carcinogenesis. 
To test this hypothesis, we investigated: (1) the role of arsenic in the generation of miRNAs in 
the human bronchial epithelial cell line, BEAS-2B, using a microRNA array; (2) detailed the 
concentration-dependent regulation of the selected individual miRNA, such as miR-190, by 
arsenic using real-time PCR; (3) co-transcription of the intronic miRNA, miR-190, and its host 
gene, talin2, by a dual luciferase reporter gene assay and real-time PCR; (4) the potential target 
genes of miR-190 using in silico analysis, western blot, and 3’UTR reporter assays, and (5) the 
overall carcinogenic potential or cellular responses to arsenic-induced miR-190 through transient 
and stable overexpression of miR-190, followed by analytical tests such as western blot, 
proliferation assay and soft agar assay.  The data obtained from this study show that arsenic is 
capable of inducing expression of several miRNAs, most remarkably miRNA-190 whose 
expression correlated with that of its host gene talin 2.  In silico analysis of possible miR-190 
targets indicated that this miRNA may be involved in tumor formation by targeting multiple 
proteins including PHLPP, an Akt phosphatase, and TP53INP1, a key cell apoptosis regulator. 
PHLPP is a known tumor suppressor that inactivates Akt by dephosphorylating serine 473, 
leading to decreased cell growth and enhanced apoptosis.   PHLPP reporter assays indicate that 
miR-190 is a genuine PHLPP repressor that binds to the 3’UTR of the PHLPP mRNA. Kinase 
activation analysis demonstrated that miR-190 is able to mediate arsenic-induced Akt activation 
in a PHLPP dependant manner.  Furthermore, overexpression of a miR-190 precursor could 
enhance the expression of VEGF, a growth factor downstream of Akt signaling responsible for 
enhancing tumor growth through neoangiogenesis and epithelial cell proliferation. Stable over 
expression of miR-190 led to an increase in colony number and size in a soft agar assay. This 
increase in colonies was accompanied by an increase in basal Akt phosphorylation and VEGF 
expression. 
Taken together, these data suggest that arsenic is capable of inducing expression of 
miRNAs that may play critical roles in arsenic-induced carcinogenesis. Specifically, arsenic-
induced miR-190 expression led to increased Akt activation and overall proliferation through 
repression of PHLPP. Accordingly, these findings not only revealed a novel mechanism of 
arsenic-induced carcinogenesis but also highlight a pathway which may be a good target for 
therapeutic intervention. Inhibiting miR-190 would lead to an elevated expression of PHLPP 
which inactivates Akt, and consequently, reduces potential for the malignant transformation of 
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I. Introduction and Significance:           
The development of human cancers following environmental or occupational exposure to 
arsenic is an issue of significant concern. Residing or working in environments in which there 
are high concentrations of arsenic is significantly associated with increased cancer risk. 
Understanding how these malignancies develop is necessary for proper treatment after 
development of the disease and potentially may lead to prophylactic mechanisms where arsenic 
exposure cannot realistically be limited. Arsenic-induced cancers are thought to be mediated by 
activation of biological pathways involved in tumorigenesis. The discovery of a class of small 
RNAs known as microRNAs (miRNA) introduced a new paradigm in thinking about protein 
synthesis and expression. miRNA are small cellular regulators which can either drastically or 
subtly alter the expression of proteins in biologically relevant ways. They have been identified as 
key regulators of cell differentiation as well as cancer initiation and progression. Understanding 
how the expression of miRNAs are altered by arsenic exposure will provide important insights to 
how arsenic induces carcinogenesis and may provide clues as to how these malignancies may be 
treated.  
II. Arsenic Exposure and Functions: 
Epidemiology:  
Arsenic is a common element found in nature including soil, rocks, water, air, etc. While 
high dose exposure to arsenic is lethal, low dose exposure over a long period of time has proved 
to be carcinogenic in humans. The International Agency for Research on Cancer (IARC) and the 
World Health Organization (WHO) have classified arsenic as a group I human carcinogen. 
People who live in areas with high levels of arsenic in the drinking water or work where arsenic 
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exposure is common are more prone to develop cancers of the skin, lung, liver, kidney, and 
bladder [1]. While the carcinogenicity of arsenic in laboratory animals was once controversial 
[2], a growing body of evidence supports this concept in experimental models using multiple 
rodents and multiple routes of exposure [3]. The route of entry for arsenic would appear to be 
related with the origin of the malignancy; e.g., frequent foot contact with arsenic-containing soil 
causes skin cancer, inhalation of air or dusts mixed with arsenic induces lung cancer or bladder 
cancer, and ingestion of arsenic-contaminated drinking water may result in liver or kidney 
cancers. This may not always be the case. Some work has shown that the increased risk of lung 
cancer is largely independent of route of entry, with the mortality rate ratio estimate being 
comparable between inhalation and ingestion [4]. Additionally, if arsenic is acting as a co-
carcinogen, with UV radiation for example, ingested arsenic could lead to increased skin cancer 
risk [5]. In lung cancer, relatively low levels have been observed to increase risk to lung cancer. 
In a study of populations living near smelting plants in Japan, concentrations of arsenic in the air 
as low as 1.77 ng/m
3
 produced a significant increase in the standard mortality rate of lung cancer 
[6]. This concentration is considerably lower than the OSHA permitted exposure level of 10 
µg/m
3 
over an 8-hour time weighted average (OSHA occupational safety and health standards). 
All of these observations support the notion that environmental or occupational exposure to 
arsenic poses a significant risk for developing cancer. Understanding how this occurs is crucial 
to treating arsenic-induced disease and may provide insights into the development and treatment 
of other diseases associated with environmental exposure.  
Arsenic Biochemistry; Uptake: 
 The major environmental arsenic species include arsenate (arsenic pentoxide, H3AsO4) 
and arsenite (arsenite trioxide, As3(OH)3). At physiological pH, arsenate can be reduced to 
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arsenite which is credited with most of the intracellular and pathological effects.  The uptake of 
arsenite into both prokaryotic and eukaryotic cells has been shown to be achieved by 
aquaglyceroporin proteins, which are members of the aquaporin family. Aquaporin proteins are 
responsible for the flow of water in and out of cells and some of which are capable of 
transporting additional molecules in concert with water.  In E. coli, the protein likely to be 
responsible for arsenite transport is GlpF. GlpF is a glycerol facilitator that is capable of 
transporting antimonite, a metalloid with properties similar to arsenite [7]. The mammalian 
aquaglycerporin proteins responsible for arsenite uptake into cells are AQP7 and AQP9.    Liu Z. 
et al. showed the functionality of these proteins to transport arsenite by cloning of AQP9 and 
microinjection of AQP7 [8]. AQP9 was cloned into strains of S. cerevisiae that had FPS1 
(Arsenite uptake) and Acr3p and Ycf1p (Arsenite efflux) deleted or mutated. AQP9 was then 
capable of making the mutated strains more sensitive to arsenite exposure. Expression of AQP7 
was unable to be achieved in the S. cerevisiae system. Instead, capped cRNA of AQP7 was 
microinjected into Xenopus oocytes and enabled dramatic uptake of arsenite. This finding 
suggests that mutation or loss of these transporters in human cells could make an individual more 
susceptible or resistant to arsenic exposure, increasing cancer risk or reducing treatment efficacy 
in the case of acute promyelocytic leukemia.     
 
Arsenic Metabolism:  
After arsenic is taken up, it is metabolized by the cell which includes methylation, 
reduction, oxidation, sequestration and efflux. Following these steps, as many as six different 
arsenic species can exist including arsenate, arsenite, monomethylarsonate (MMA(V)), 
monomethylarsonous acid (MMA(III)), dimethylarsinic acid (DMA(V)), and dimethylarsinous 
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acid (DMA(III)) [9] (Fig. 1). Arsenate is reduced to arsenite before it can be sequestered or 
eliminated, which is achieved by arsenate reductase enzymes. While reduction of arsenate in 
mammalian organisms is not as well understood as bacterial or yeast systems, recent research has 
identified the reductases responsible for metabolism and subsequent elimination in human cells. 
One such protein is the enzyme purine nucleotide phosphorylase, also called arsenate reductase, 
which was isolated from human liver extract and was capable of reducing arsenate [10]. This 
reduction occurs in the presence of an inosine and a thiol compound. 
 
Arsenic Export:  
The export of arsenic from mammalian cells is achieved by human multidrug resistance 
protein 1 (MRP1/ABCC1) and 2 (MRP2/ABCC2). They are members of a superfamily of 
transport proteins known as the ATP binding cassette superfamily. The MRP proteins export 
many different substrates, which are usually stimulated by the presence of glutathione (GSH) 
that is co-transported with or conjugated to the substrate. The ability to export arsenic was 
originally described by Cole et al. while demonstrating the ability of MRP to confer resistance to 
multiple drugs [11]. The efflux of drugs by MRP was later shown to be catalyzed by the presence 
of GSH within cells [12]. Depletion of GSH from cells was able to reverse the resistance 
conferred by MRP overexpression in cell lines. Additionally, arsenite was observed to cause an 
MRP-mediated release of GSH from cells. The MRP1-mediated arsenite efflux from cells 
mediated via MRP1 was later shown to be dependent upon the presence of GSH S-transferase 
P1-1 (GSTP1-1) [13]. This protein catalyzed the formation of arsenic triglutathione (As(GS)3) 
which was efficiently eliminated from cells. Cells without GSTP1-1 could not transport arsenite 
out of the cell regardless of the presence of GSH. Arsenite is then filtered by the kidneys and 
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stored in the bladder before elimination. As arsenite is more bioactive than arsenate, the bladder 
is a common site of arsenic-induced carcinogenesis. 
 
Carcinogenic Functions:  
There are three main mechanisms by which the various arsenic species are capable of 
interacting with biological systems to induce carcinogenesis. Arsenic species are known to 
generate reactive oxygen species but not reactive nitrogen species [14]. They can also change the 
methylation state of DNA, leading to either hypermethylation or hypomethylation. Finally 
trivalent arsenic species are able to bind to sites on peptides and proteins, commonly sulfhydryl 
groups [15].  
One of the more recently discovered mechanisms of carcinogenesis for arsenic within 
cells is its ability to bind to zinc finger domains. Arsenic competitively binds to cysteine residues 
within the zinc fingers inhibiting functions that would normally be active when zinc is bound. 
This has been demonstrated by analysis of the inhibition of arsenite on poly (ADP-ribose) 
polymerase 1(PARP-1)-mediated DNA damage repair [16]. Arsenite was shown to compete with 
zinc for binding to the cysteine residues of the zinc finger domain of PARP-1. This competitive 
binding leads to the inhibition of PARP-1 activity, and an increase in the amount of ultraviolet 
radiation-induced 8-hydroxyl-2′-deoxyguanine DNA lesions. This resulted in an increase in 
carcinogenesis of skin cell lines indicating a mechanism for the co-carcinogenesis of arsenic with 
ultraviolet radiation. This is an important discovery that indicates additional roles for arsenic as a 
zinc finger domain binder, and it will be interesting to see what additional zinc finger proteins 
arsenic may bind.  
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One signaling protein indicated to be involved in arsenic induced carcinogenesis is ERK. 
A crucial study that indicated this activity was performed by Huang et al.[17].  They showed that 
doses of arsenite from 0.8 µM to 200 µM were capable of activating ERK in mouse epidermal 
cells. They further showed that it was this ERK activation that was critical for the induction of 
cell transformation. When dominant negative ERK2 was expressed, there was a dramatic 
reduction in cell transformation in response to arsenic exposure [17]. The mechanism by which 
arsenic activates ERK appears to be through the Epidermal Growth Factor Receptor (EGFR) and 
associated pathways. Arsenite does not activate EGFR through ligand binding, but through the 
alternate mechanism of c-Src activation [18]. This activation of Src may be due to the sulfhydryl 
binding activity of arsenite, binding to an inhibitory phosphotyrosine residue causing oxidation, 
and consequent activation of Src. Active Src can then bind to EGFR promoting phosphorylation 
and activation of the receptor [18]. Downstream of EGFR activation is the activation of the 
adaptor proteins Grb2 and Shc. Activation of these proteins by arsenic has also been observed 
and are directly responsible for the activation of the MAP kinase cascade upstream of ERK [19]. 
Active ERK is also known to activate several transcription factors involved in cell survival and 
proliferation including the proto-oncogene c-myc.  
A second kinase that has been studied as having a relationship to arsenic-induced 
carcinogenesis is JNK and its downstream transcription factor AP-1. Early studies examining 
arsenic-induced JNK expression used high doses of arsenic over either short or long time points 
which induced apoptosis [20-22]. Studies using lower doses showed arsenic-induced JNK 
activation leads to an increase in GADD45α expression inducing cell cycle arrest [23, 24]. 
However, additional studies showed that low dose exposures performed over mid to long term 
time points (24 hrs-months) was shown to induce activation of JNK and AP-1 and cause 
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proliferation and transformation of cells [25]. Additionally, inhibition of JNK in arsenic-trioxide 
treated human keratinocyte cell line led to an increase in apoptosis, suggesting an anti-apoptotic 
role of arsenic-induced JNK activation [26]. 
Arsenic has also been shown to be involved in the activation of Akt. Activation of Akt is 
one of the most well known anti-apoptotic and proliferative signals within the cell. Akt is 
activated by phosphorylation on two residues, serine 473 and threonine 308. Elevated expression 
of the PI3K/Akt pathway is often observed in various cancers including non-small cell lung 
cancer, breast cancer, and pancreatic cancer [27]. Downstream effectors of Akt have roles in 
apoptosis inhibition, cell cycle regulation, metabolism, stress response, and protein translation 
[28]. Negative regulators of the Akt pathway include PTEN and PHLPP. PTEN 
dephosphorylates PIP3 upstream of Akt, inhibiting recruitment of Akt and PDK1 to the 
membrane and PHLPP directly dephosphorylates Akt at serine 473 [29]. Phosphorylation of 
serine 473 by arsenic has been observed in mouse epidermal cells [30] and human bronchial 
epithelial cells [31]. Activation of Akt by arsenic trioxide has also been observed in leukemic 
cells where arsenic is used as a therapeutic agent. Inhibition of this activity greatly enhances the 
sensitivity of the leukemic cells to arsenic-induced apoptosis, enhancing its therapeutic effect 
[32]. Additionally, long term low dose arsenic exposure (0.5-2.0 µM for 3 mo-1yr) of human 
small airway epithelial cells showed an increase in phosphorylation of Akt and ERK. While 
colony number and plating efficiency for these cells were greatly increased, the proliferation rate 
stayed largely the same compared to control cells [33].  
 Occupational or environmental exposure to arsenic poses a significant health risk due to 
its carcinogenic activity. Although arsenic is an established carcinogen, the mechanisms by 
which tumorigenesis takes place is not fully understood. Further research is required to 
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understand the biological activity of arsenic so that diseases caused by arsenic may be more 
effectively treated. 
III. MicroRNA Expression, Function and Regulation 
The discovery of microRNA (miRNA) revealed a new mechanism for the regulation of 
gene expression. MiRNAs are short, approximately 22 nucleotide long, RNA molecules which 
are capable of targeting partially or fully complementary sequences in the 3’UTR of mRNA 
transcripts. The pairing of miRNA with target mRNA represses the expression of the mRNA 
leading to reduced protein expression, through various mechanisms. Since their discovery, 
miRNA have been observed to be involved in nearly every biological process including 
embryonic development, self renewal of stem cells, immune response, neurological function, and 
cancer development and progression.  
 MicroRNA were first discovered in 1993 through the close collaboration of Ambros [34] 
and Ruvkun [35]. While studying the developmental regulation of LIN-14 protein expression in 
C. elegans, they found that the lin-4 gene which was known to repress LIN-14 did not encode a 
protein but a very short RNA sequence. Together they observed within the LIN-14 3’UTR, a 
sequence partially complementary to the short lin-4 sequence. This observation suggested a 
mechanism by which repression could occur through antisense binding thereby reducing protein 
levels. The next miRNA to be discovered was let-7 in early 2000 [36]. Also in C. elegans, this 
miRNA was observed to have complementary sites in a number of genes including lin-41 whose 
repression by let-7 was experimentally validated. Since these two discoveries much work has 




Mammalian MicroRNA Biogenesis:  
The biogenesis of miRNA involves three distinct processes including transcription 
followed by processing in the nucleus and further processing in the cytoplasm. Transcription of 
miRNA is usually performed by RNA polymerase II creating long RNA transcripts which 
contain hairpin structure(s) known as primary miRNA (pri-miRNA). The hairpin structures are 
cleaved from the pri-miRNA to form precursor miRNA (pre-miRNA). This pre-miRNA is 
exported to the cytoplasm and further processed to form the single stranded mature miRNA (Fig. 
2). Each of these steps is highly controlled by multiple regulatory proteins indicating the 
importance of miRNA expression and function within the cell.  
 
Genomic Organization and Transcription:  
The genes encoding miRNA are characterized into three major categories; intergenic, 
intronic and exonic [37]. Most miRNAs are considered to be intergenic, meaning they have their 
own promoter regions. Many of intergenic miRNA can be  clustered together forming 
polycistronic transcription units, encoding multiple miRNAs [38].   Some miRNAs are intronic, 
that is they are located within the introns of host genes, and are subject to transcriptional control 
of the host’s promoter. The miRNA-containing introns are spliced from the larger RNA before 
the miRNA is processed further. Exonic miRNAs are the rarest, accounting for approximately 
10%, and they must be processed out of the exons of transcripts which likely become non 
functional [39].   
Generation of new mature miRNA molecules begins with transcription of pri-miRNAs 
that are typically transcribed by RNA pol II. These transcripts are normally several kilobases in 
length and contain stem loop structures characterized by a ~33 nt stem, terminal loop and 
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flanking single stranded sequences (Fig.2). The activation of transcription is controlled by pol II 
associated transcription factors allowing for highly variable miRNA expression depending upon 
the cellular context [40].  
 
Processing by the Microprocessor and Nuclear Export.  
After transcription the stem-loop structures must be cleaved from the RNA transcript, 
creating the ~70 nt pre-miRNA. This cleavage is performed by the Drosha microprocessor, a 
complex of proteins including the RNase III enzyme Drosha and DiGeorge syndrome critical 
region 8 (DGCR8) (Fig. 3). This complex binds to the stem of the pri-miRNA to define the 
appropriate cleavage site for formation of the pre-miRNA. DGCR8 is believed to bind to the 
base of the pri-miRNA stem, recognizing the single stranded RNA on both sides, and act as a 
molecular ruler directing Drosha to cleave 11 base pairs up the stem from the single stranded 
sequences [41, 42]. The resulting pri-miRNA stem loop contains a 2 nt 3’ overhang that is 
typical for RNase III mediated cleavage [43].   
After cleavage by the microprocessor the pre-miRNAs are bound to Exportin 5 and are 
shuttled out of the nucleus in a Ran-GTP dependant manner [44]. The proper length stem, and 3’ 
overhang of the pre-miRNAs are required for Exportin 5 binding and transport [45]. This 
requirement may ensure that pre-miRNAs with the proper sequence are exported to the 
cytoplasm. Exportin-5 may also play a role in protecting pre-miRNAs from degradation before 
export. Reduction in the amount of Exportin 5 results in reduced mature miRNA in the 
cytoplasm without a buildup of pre-miRNA within the nucleus, suggesting degradation. Once in 
the cytoplasm Ran-GTP is hydrolyzed to GDP, and the miRNA is released for further 
processing.  
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In some cases miRNAs can avoid the processing step from pri-miRNA to pre-miRNA 
when the miRNA sequence comprises the entire intron. In this case splicing of the intron from 
the larger RNA transcript creates the pre-miRNA molecule ready to be transported to the 
cytoplasm. These miRNAs are referred to as mirtrons [46]. Mirtrons can bypass the Drosha 
processing step by being processed by the mRNA splicing machinery [46, 47].  These 
specialized pri-miRNAs are characterized by having G and C rich regions at the 5’ and 3’ end of 
the intron for mammalian genes, and U rich regions at both ends for invertebrate genes [48]. It is 
unclear whether this is a type of primitive miRNA and whether there is an evolutional reason for 
these types of miRNAs [48].  
 
Processing by Dicer and RISC Incorporation.  
In the cytosol, miRNAs are further processed by the RNase III enzyme Dicer by 
removing the loop to create a double stranded RNA about 22 nucleotides long [49-51]. One 
strand is removed and degraded, while the mature miRNA is incorporated into an RNA-induced 
silencing complex (RISC). Cleavage of the pre-miRNA by Dicer is directed by its domain 
structure. The PAZ domain of Dicer recognizes the 3’overhang left behind by Drosha 
processing. The rest of the protein then acts as a molecular ruler guiding the cleavage of pre-
miRNA loop structure [52]. Dicer is known to interact with two proteins; TAR RNA-binding 
protein (TRBP) [53] and PACT [54]. It is not known whether either of these proteins is involved 
in modulating Dicer’s processing function. They do however aid in loading of the miRNA into 
the RISC. Depletion of TRBP and PACT causes reduced miRNA activity, and reduced mature 
miRNA accumulation respectively. After cleavage by Dicer, the mature miRNA is loaded onto 
an Argonaute protein (Ago) of the RISC complex. One strand of the miRNA duplex is selected 
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for degradation while the mature miRNA remains bound to the RISC. This selection is based 
upon the thermodynamic stability of the individual strands. The strand with the most 
thermodynamically stable 5’ end is usually selected for degradation [55]. The Argonaute protein 
makes up the core of the RISC of which there are four family members in humans AGO1-4. All 
of these family members are capable of binding miRNAs, however AGO2 and to a lesser extent 
AGO3 appear to be the predominantly active family members [56, 57]. The mature miRNA then 
guides the miRISC to target sites in the 3’UTRs of mRNAs. 
 
Regulation of Biogenesis: 
 The biogenesis of miRNAs occurs in a multi-step process with many regulatory proteins 
that give rise to control of abundance at several levels. This possibility was first suggested by an 
observation of post-transcriptional repression during cell development [58]. Indeed, the Drosha 
cleavage event is subject to regulation by several proteins including p68, p72, Smad, p53, Ars2, 
and Estrogen receptor alpha (ERα) (Fig. 3). The topic of regulation at the Drosha processing step 
is reviewed elsewhere [59] and supplied in the appendix.   
The two DEAD-box RNA helicases p68 and p72 have both been shown to be involved in 
modulating Drosha processing. The first association of the DEAD-box helicases with Drosha 
was observed by Gregory et al. when they isolated two multi-protein Drosha-containing 
complexes. The smaller one, termed the microprocessor contained Drosha and DGCR8, while 
the larger complex contained nearly twenty additional proteins. The smaller complex was 
deemed sufficient for miRNA processing, while a role for the larger complex which contained 
the helicases, was not yet determined [60]. Further research showed that p68 and p72 were 
critical for the expression of a subset of miRNAs as well as 5.8s rRNA. Knock down of these 
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two proteins also resulted in either embryonic lethality or neonatal lethality [61].  The exact roles 
of these proteins within the complex have still not been determined. One possibility is as 
helicases they may be involved in unwinding the long pri-miRNA stems so Drosha may more 
efficiently cleave off the pre-miRNA, or expose binding elements for additional proteins to bind 
and modulate processing. 
Association of R-Smad proteins with the microprocessor has been shown to enhance the 
expression of several miRNAs including miR-21 and miR-199a in response to TGF-β or BMP4 
[62]. Smad proteins with the exception of Smad4 are capable of binding directly to p68, which 
help to facilitate an accumulation of pre-miRNA. Furthermore upregulation of miR-21 leads to a 
decrease in PDCD4 and PTEN, the well known targets of miR-21, indicating a new mechanism 
for TGF-β in cancer pathology [62].  An additional study identified a conserved sequence similar 
to a Smad binding element (SBE) in the miRNAs regulated by Smads. This sequence is located 
within the stem of regulated miRNAs and is termed an RNA Smad binding element (R-SBE).  
Smad-bound pri-miRNAs efficiently recruit Drosha for processing which enhances the formation 
of pre-miRNA and increases expression of the mature miRNAs [63]. The presence of this 
element within the stem of pre-miRNAs easily identifies the subset of miRNAs that are regulated 
by TGF-β and BMP4.   
The tumor suppressor protein p53 is also capable of binding to the microprocessor and 
modifying the expression of multiple miRNAs. It was observed that exposure to DNA damaging 
agents increased the abundance of specific pre- and mature miRNAs without increasing pri-
miRNA abundance, suggesting a post-transcriptional regulatory mechanism.  Capable of binding 
to p68 as well as p72, association of p53 with pri-miRNA enhances recruitment of Drosha, 
leading to an enhanced processing of pri-miRNA and increased generation of  pre-miRNA [64].  
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While no consensus sequence or other identifying characteristic has been found to easily identify 
those miRNA post-transcriptionally regulated by p53, the miRNA whose abundance are 
regulated have functions within the cell that are consistent with the pro-apoptotic activities of 
p53. In addition to post-transcriptional regulation, p53 has also been shown to activate 
transcription of miRNA. The transcriptional activation of miR-34a by p53 has been confirmed, 
and miR-34a has been shown to be involved in mediating the apoptotic activity of p53 [65].   
   Association of these proteins with the microprocessor appears to enhance the regulation 
of some but not all miRNAs. The complete identification of all members of these subsets will 
confirm whether or not the miRNAs with enhanced processing and expression regulate similar 
biological processes to that of their modulators.  
 
miRISC Functions: 
 The mechanisms by which miRNA repress protein expression have yet to be fully 
delineated. The miRISC complex containing Ago, the miRNA, and Dicer is associated with 
several additional proteins forming the miRNP or micro-ribonucleoprotein that is responsible for 
directing the downstream function. To date, there appear to be two main mechanisms for 
miRNA-mediated repression following target recognition; first, mRNA deadenylation and 
degradation and second, inhibition of translation.  
 
Target Recognition: 
 Repression of mRNA by miRNAs is achieved by sufficient recognition and binding of 
the miRNA to a miRNA recognition element (MRE) within the 3’UTR of a target mRNA. For 
most miRNAs the region that appears to be most important for recognition of a target mRNA 
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from an evolutionary standpoint is bases 2-8 on the 5’ end of the miRNA [66]. This region is the 
most highly conserved across species within the miRNA as well as the MRE. It has been shown 
however that many miRNAs can violate this seed sequence rule. Examples of this include miR-
10a which targets the 5’UTR using a non-seed site [67]. Additionally, miR-24 inhibits 
expression of cell cycle genes including E2F2 by binding unpredicted “seedless” MREs [68]. 
While no seed region was identified, a high degree of complementarity was sufficient for target 
recognition. 
 
Deadenylation and Degradation of Target mRNA:  
While the mechanisms for miRNA induced repression of protein expression are still 
being studied and are of some debate, target mRNA deadenylation and degradation have been 
well established [69]. The protein or protein family most critically involved in this process is 
GW182 or TNRC6C in humans. This protein has been demonstrated to be necessary for the 
assembled miRISC to repress gene expression. In humans GW128 physically associates with 
Ago proteins and is involved in mediating miRNA-induced repression [70], and it appears that 
the c-terminus and an RRM domain both contribute to this activity [71, 72]. Knock down of 
GW182 expression within cells decreases both miRNA function and the presence of p-bodies 
which are cytoplasmic foci of mRNA silencing and degradation [70]. GW182 is responsible for 
recruitment of the CAF1 and NOT1 deadenylases to the miRNP-bound mRNA target [73, 74]. 
Additionally it has been shown that Ago proteins interact directly with CAF1 and CCR4 
deadenylases, and that GW182 interacts with poly-A binding protein (PABP) which acts as a 
coactivator for miRNA-mediated repression [75].  Deadenylation occurs by recruitment of the 
DCP1:DCP2 complex followed by decapping. Finally, XRN1 mediates exonucleolytic cleavage 
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and degradation of the target mRNA. While the deadenylase complex, decapping complex and 
XRN1 are all p-body components, the formation of p-bodies does not appear to be necessary for 
the repressive activity of miRNA [76]. Some results have shown that repression is mainly an 
effect of translation inhibition, and not mRNA degradation. GW182 may also function in this 
regard as it is also capable of repressing protein expression when the deadenylase complex is not 
present in Drosophila cells [77].   
 
Inhibition of Translation: 
 The inhibition of translation by miRNA has been observed, and this mechanism of 
repression is widely accepted. There is, however, little agreement concerning whether the 
inhibition occurs at the onset of translation or at post-initiation steps. Multiple laboratories have 
presented data suggesting that repression occurs at initation [78, 79]. Inhibition of initiation has 
been observed as an effect of the miRNP binding to translation initation factors, such as the 
eukaryotic initation factors or eIFs. Observations have been made of miRNA complexes 
inhibiting the function of eIF4E, [79] eIF4F, of which eIF4E is a component, [80] and promoting 
the effect of eIF6, a factor which inhibits the binding of 40S and 60S ribosomal subunits to the 
mRNA[81]. In most cases, utilization of a reporter including an internal ribosome entry site or 
IRES, abolishes the repressive effect of the miRNA, indicating that proper m
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mediated translation is necessary for repression [78-80].  
While many studies indicate a role for inhibition at initiation, several other studies 
provide evidence that repression may occur at post-initiation steps. These studies are highlighted 
by reports that miRNPs can associate with polysomes, and that repression is not affected by the 
introduction of an internal ribosome entry site or IRES. A model was used where siRNA for 
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CXCR4 was used to knock down a luciferase reporter with 6 binding sites in its 3’UTR with or 
without an IRES. The presence of the IRES had no effect on the ability of the siRNA to repress 
luciferase expression. Repressed RNA was associated with polysomes indicating that initation 
had already taken place, but full length mRNAs were not synthesized indicating pre-mature 
ribosome drop-off as the mechanism of repression [82]. Similarly when miRNA binding sites 
were inserted into a 5’UTR in which an IRES was present or when Ago2 was tethered to either 
the 5’or 3’UTR, repression was still observed indicating a mechanism at post-initiation steps 
[83]. A few additional studies suggest other post-initation mechanisms such as miRNA-mediated 
recruitment of proteases to degrade nacent polypeptides [84], however much work needs to be 
done before this repressive mechanism can be fully elucidated. 
 
Regulation of Repression:  
Similar to miRNA biogenesis, miRNA-mediated repression is also regulated by multiple 
factors including RNA-binding proteins that interact with the miRNP complex and alter its 
function to either increase or decrease repression. The TRIM-NHL family of proteins, TRIM32 
specifically in humans, has been shown to interact with miRNPs associated with several 
miRNAs including let-7a, miR-214, and miR-134. TRIM32 was also shown to enhance the 
repressive activity of let-7a as indicated by a luciferase reporter [85]. Modulating proteins have 
also been shown to inhibit miRNA-based repression. Examples of this regulation include 
translocation of HuR to the cytoplasm after cellular stress. HuR protein binds to AU-rich 
elements within the 3’UTR of CAT-1 mRNA and releases it from miR-122-mediated repression 
[86]. Additional examples of protein-induced alleviation of repression include: expression of 
Dnd1 in humans alleviates miR-221 repression of p27 [87]; the Apolipoprotein B mRNA-editing 
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enzyme polypeptide-like 3G causes exit of miRNA reporters from P-bodies [88]; and the 
inhibition of miR-134-mediated repression on Limk1 mRNA in rat neurons by brain derived 
neurotrophic factor (BDNF) [89]. 
 
miRNA-mediated upregulation of protein expression:  
Expression of miRNAs is normally associated with the repression of protein expression. 
There are a few reports however of circumstances in which miRNAs have been observed to 
increase protein levels. One of these cases is miR-10a. When binding to the 5’UTR of mRNAs 
that encode ribosomal proteins, translation is enhanced. This enhancement is capable of 
overcoming the repression of expression experienced during amino acid starvation, and is 
required for translation initiation after Ras overexpression [67].  A second example reported by 
Vasudevan et al. suggests two mechanisms by which miRNA might enhance protein expression. 
They observed AU-rich elements (ARE), conserved regions within 3’UTRs, acting as an 
activation signal by recruiting Fragile X mental retardation-related protein 1 (FXR1) and AGO 
associated with miRNPs containing miRNAs. The miRNA in this case was responsible for 
directing the association of these proteins with the ARE and causing enhanced protein expression 
[90]. The second mechanism they reported acted as a switch from repression to expression. The 
miRNA let-7 was shown to repress translation of target mRNAs during cell proliferation, and 
switch to up-regulation upon cell cycle arrest. These observations indicate that the cellular role 
of miRNAs may be much broader than initially observed, being involved in repression, up-
regulation, and binding to other areas than just the 3’UTR. 
IV. MicroRNA and Cancer: 
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 Since the discovery of miRNA there have been implications for a role of this small but 
potentially powerful cellular regulator in cancer development and progression. The first miRNAs 
lin-4 and let-7 were discovered as having a role in C. elegans development. Later, miRNAs such 
as miR-21 and miR-155 emerged as having significant influence on the development and 
progression of cancer, targeting tumor suppressor genes, and enhancing tumorigenesis. 
 
Oncosuppressive miRNAs: 
 The first study that directly linked expression of miRNA with the pathogenesis of human 
cancers revealed that miR-15a and miR-16-1 were lost as a consequence of deletion of 
chromosome 13q14 during development of chronic lymphocytic leukemia [91]. A follow up 
study on these miRNAs showed that miR-15a and miR-16-1 targeted the oncogene BCL2. Loss 
of 13q14 then causes an overexpression of BCL2, protecting cells from apoptosis and enhancing 
leukemogenesis [92]. Other tumor suppressive miRNAs exist such as let-7. This miRNA, aside 
from its roles in C. elegans, targets oncogenes such as RAS [93], HMGA2 [94], and MYC [95].  
Experssion of the let-7 miRNA family in breast cancer initiating cells represses proliferation, 
mammosphere formation, and tumor formation in mouse models [96]. Additionally, in small-cell 
lung cancer, the let-7 family represses tumor growth and enhances apoptosis [97]. Another 
miRNA commonly repressed in cancer, miR-145 [98, 99], has significant tumor suppressive 
functions. Activation of the p53 pathway increases expression of miR-145 which directly 
represses expression of c-MYC, inhibiting tumor growth [100]. The regulation of receptor 
tyrosine kinases by miRNA has also been observed, and loss of this regulation enhances cancer 
cell proliferation. One example of this is the EGF receptor family. Expression of both HER-2 
and HER-3 can be repressed by miR-125a and miR-125b [101]. HER-3 can also be regulated by 
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miR-205 in breast cancer. Forced expression of miR-205 reduces breast cancer cell growth and 
enhances sensitivity to tyrosine kinase inhibitors [102].  
 
Tumor promoting miRNAs:  
While many miRNAs which can function as as tumor suppressors, there are equally many 
that act as tumor promoters. These miRNAs that have roles in promoting tumorigenesis or cancer 
progression have been termed oncomirs. A commonly overexpressed miRNA, miR-21 has been 
observed in many solid tumors including lung, breast, ovary and others. This miRNA has been 
shown to directly target tumor suppressor genes PDCD4 [103], PTEN [104, 105], and TPM1 
[106]. Originally miR-155 was shown to be upregulated in multiple lymphoma subtypes [107]. 
Since then, overexpression of miR-155 has been observed in many different malignancies 
including cancers of the lung, breast, colon, cervix, pancreas and thyroid [108]. Expression of 
miR-155 is achieved by transcription of the BIC gene, the retroviral integration site for avian 
leukosis virus which induces B-cell lymphomas [109].  Targets of miR-155 indicating its 
oncomir status include FOXO3a [110], SOCS1 [111], SMAD5 [112], TP53INP1 [113], and 
other additional tumor suppressor proteins. Another common oncomir or set of oncomirs is miR-
221/222. These two miRNAs which are coordinately expressed are involved in multiple cancers 
including breast cancer where they target p27Kip1 [114] and gastric cancer by targeting PTEN 
[115]. The pair of miRNAs has also been identified as targeting the pro-apoptotic protein PUMA 
[116] and estrogen receptor alpha [117]. Thus far, most of the miRNA targets mentioned have 
roles in proliferation or apoptosis avoidance. However, miRNAs have also been shown to be 
involved in cancer cell invasion and metastasis.  
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miRNA expression profiling:  
The purpose of profiling of miRNA expression in various cancers, cancer cell lines or  
patient samples, is to identify whether a specific miRNA expression signature exists for tumors 
or tumors of a specific background. Identification of such a signature could help in various ways 
from diagnosis to therapeutic intervention. The first such signature was identified in chronic 
lymphocytic leukemia (CLL).  A 13 gene signature was defined that identified prognostic 
factors, and expression was independent of disease progression [118]. Expression signatures for 
many different malignancies have since been identified including lung [119], pancreatic [120], 
liver [121] and others. Expression profiling for miRNA has also been used to differentiate tumor 
subtypes for the potential use as a diagnostic or prognostic tool [122]. 
 
miRNAs in cancer therapeutics: 
 The ability of miRNAs to be involved in multiple stages of cancer development and 
progression where individual miRNAs targeting several proteins within the same or similar 
pathways indicates that they may be good targets or tools for therapeutic intervention. As 
mentioned above, when miRNAs are manipulated in vitro or in vivo, they have the ability to 
induce or reverse cancer phenotypes. However, the hope of miRNA in cancer therapeutics has 
yet to be realized. Clinical trials for miRNA in cancer and other diseases have however been 
started, with some promising results. One example of this is miR-122 in hepatitis C infection. 
The hepatitis C virus uses miR-122 to activate the transcription of its genome. As miR-122 is 
largely liver specific, repression of its expression using a locked nucleic acid (LNA) antagonist, 
SPC3649 that is also liver specific represses HCV replication and viremia [123]. Phase 1 clinical 
trials for this therapeutic are underway and phase 2 trials are in planning stages [124]. Several 
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additional clinical or preclinical trials are also being performed on multiple malignancies and 
diseases [124]. Several approaches are being taken in an attempt to alter miRNA levels within 
cells, to reduce or increase the expression or activity of miRNAs. This change in miRNA activity 
will hopefully reverse the disease phenotype by decreasing tumor growth and spread, or make 
resistant cancer cells more susceptible to chemotherapy. 
 Since the role of miRNA within cells is to act as regulators of protein expression, they 
have great potential to cause phenotypic changes in cells whether they are directing normal 
cellular differentiation or tumorigenesis. The expression of a single miRNA or group of miRNAs 
can be either oncogenic or oncosupressive, indicating that miRNAs can be involved in cancer 
diagnosis, prognostic prediction, and cancer therapeutics. 
Alteration of miRNA expression could greatly enhance the understanding of mechanisms 
by which arsenic induces cancer formation. Therapeutics using miRNA and miRNA pathways 
are being developed which may make miRNAs a ‘double-edged sword’ for arsenic induced 
malignancies. It is important then to study how arsenic might control the expression of miRNAs, 
understand which miRNAs are regulated and if they might be manipulated to prevent or treat 
arsenic induced disease. 
V. A Case for  microRNA-190 in Arsenic-Induced Cancer: 
Genomic Context:  
It is well known that cytoskeletal control is important in tumorigenesis. miRNA-190 is 
derived from an intronic region of the talin 2 gene on chromosome 15.  The proteins of the talin 
family include talin 1 and talin 2.  They share several highly conserved domains, such as the rod 
domain and the FERM domain, that are important for interaction with F-actin, integrin, PIP5KI 
isoforms, and focal adhesion molecules [125, 126].  Talin 2, while not as well studied as talin 1, 
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plays a role within the cell cytoskeleton. It is not known however, whether miR-190 and talin 2 
are involved in similar processes. miR-190 is located within an intronic region between exons 51 
and 52 of talin 2 that is approximately 12,800 base pairs long [127]. This location for miR-190 
has been described as an intronic exaptation, or a situation in which miRNAs arise within an 
intron of a previously existing gene where the host gene and miRNA have differing selective 
pressures [127]. In this case miR-190 is specific to bilaterian lineage, and is found within the 
intron of a gene which is much older. Evolution of miRNAs within pre-existing genes 
circumvents the need for the miRNA to evolve a promoter, perhaps speeding up and simplifying 
the process. The expression of miR-190 and talin2 has been linked at least in a correlative 
manner. The presence of miR-190 within an intron of the talin2 transcript suggests that 
expression of talin2 would also express miR-190. This relationship between the two genes 
appears to be genuine as evidenced by one study thus far [128]. An additional study has shown a 
correlation between miR-190 and talin 2 expression using microarray technologies. A correlation 
coefficient of 0.662 was found to exist between these two genes, suggesting that the expression 
of both genes coincide with one another at least in part [129]. Using bioinformatic means as well 
as ChIP-chip experiments targeting RNA polymerase II, it has been indicated that miR-190 may 
have its own promoter [130]. The predicted transcriptional start site (TSS) is located 41,530 bp 
upstream of the miR-190 transcript, within the region encompassed by the talin2 gene, and it will 
be of interest to determine what activates the expression of miR-190 independent of talin2. 
Sufficient evidence exists suggesting that miR-190 is under the control of two promoters, and 
activation of either will produce the mature miR-190 sequence. 
Function and Regulation:  
24
Early data indicating a role for miR-190 suggested that its inhibition decreased growth of 
HeLa cells. When miR-190 and several other miRNAs were individually inhibited with an 
antisense oligonucleotide, growth was inhibited without an overall change in the apoptotic 
caspase activity [131].  An additional study shows that the level of miR-190 was increased in 
granulocytes from patients with primary myelofibrosis [132].  These results suggest a role for 
miR-190 in regulating cell cycle or proliferation rate.  In a study profiling the expression of 
miRNAs in pancreatic cell lines and tumor tissues, miR-190 was one of several miRNAs found 
to be significantly overexpressed. In tumor samples, miR-190 expression was increased 88% of 
the time with an average of a 21 fold increase. Also, in comparison to normal human pancreatic 
ductal epithelium, Panc-1 as well as multiple other cell lines exhibited a greater than 5 fold 
increase in miR-190 expression [133]. MiR-190 has also been indicated to play a role in breast 
cancer. In a study identifying miRNA signatures which might predict the expression of the 
receptors for estrogen, progesterone and HER2/neu, miR-190 was predictive of estrogen receptor 
expression [134]. While ER positive breast cancers are more susceptible to endocrine-based 
therapy, miR-190 may not play a tumor suppressive or tumorigenic role in this contex. 
The expression of miR-190 has recently been studied in neurons. In response to exposure 
to the µ-opioid receptor agonist fentanyl, miR-190 levels were found to decrease. This decrease 
is caused by an increase in ERK phosphorylation via a β-arrestin 2 dependant mechanism [135]. 
ERK, when phosphorylated through β-arrestin 2, translocates to the nucleus where it can 
phosphorylate the transcription factor Yin Yang 1 (YY1). Phosphorylated YY1 has a decreased 
binding affinity for a binding site within the talin2/miR-190 promoter, reducing gene 
transcription [128]. The role of miR-190 in this context is to reduce the expression levels of 
NeuroD by binding to its 3’UTR and repressing translation through mRNA degradation. NeuroD 
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is an important neuronal protein, involved in many neuronal processes including the 
development and maintenance of dendrites. Chronic use or misuse of substances such as fentanyl 
may lead to a lasting reduction of miR-190 expression and an increase in NeuroD levels, 
possibly having pathogenic consequences [128].  
Two other studies indicate that miR-190 may play a role in the survival of neuronal cells. 
One such study examined the role of miRNA in neuroblastomas with amplification of the 
MYCN oncogene. They found that miR-190 along with miR-572 (of the survival signature 
miRNAs) were differentially expressed in tumors with MYCN amplification. A set of miRNAs 
which closely associated with event free and overall survival were compiled. Of these 15 
miRNAs only miR-190 and miR-572 were also associated with amplification of MYCN [136]. 
These observations indicate that low miR-190 expression is associated with MYCN 
amplification. Interestingly patients with low miR-190 expressing neuroblastomas have better 
event free and overall survival. These results are similar with the previous study on fentanyl in 
that the ERK/MEK/MYC pathway is involved in repressing miR-190 expression in neurons.  
The other study examined the expression of miRNA in the mouse cortex in response to ischemic 
preconditioning in order to understand the nature of the resulting neuroprotection. While the 
focus of the study was miRNAs which targeted methyl-CpG binding protein 2 (MeCP2), the 
miRNA array analysis revealed an increase in the expression of miR-190 [137]. This result could 
indicate that miR-190 expression is increased in response to cellular stress within the brain, and 
thus may be involved in cell survival. While these two studies along with the previous study may 
potentially indicate an anti-tumorigenic role for miR-190, it should be noted that all studies are 
performed on neuronal cells and this may represent a cell type specific phenomenon.  
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The expression of miR-190 has been linked with survival and proliferation of cells since 
its discovery. Its regulation by ERK indicates that it could be regulated by arsenic exposure. 
Potential downstream targets of miR-190 include pro-apoptotic proteins such as PHLPP and 
Tumor protein 53 induced nuclear protein 1 (TP53INP1). While previous evidence suggests that 
miR-190 is negatively regulated by ERK, it is possible that this effect is cell context specific, and 
positive regulation by ERK activation is still likely. This sets up a potential pathway where ERK 
activation by arsenic exposure might increase expression of miR-190, repressing PHLPP, 
prolonging or enhancing Akt activity, and enhancing growth, survival or tumorigenicity. 
VI. PHLPP Expression and Regulation: 
Discovery: 
 One of the potential targets of miR-190 predicted by multiple algorithms freely available 
online is PH-domain and leucine rich repeat protein phosphatase (PHLPP), also known as 
suprachiasmatic circadian oscillatory protein (SCOP). SCOP was discovered in the rat 
suprachiasmatic nucleus and is expressed with a circadian rhythm [138].  The domain structure 
of SCOP was determined to contain a plekstrin homology (PH) domain, as well as a leucine rich 
repeat region, a leucine zipper, a protein phosphatase 2C (PP2C)-like domain and a glutamine-
rich region. This domain structure indicates that SCOP may have important signaling functions 
in the cytoplasm as the PH domain is important for membrane localization and the phosphatase 
domain may terminate or activate certain signals. The leucine zipper however indicates that this 
protein may also have roles within the nucleus, suggesting that this protein may play a number of 
different roles [138]. SCOP (hereon referred to as PHLPP) was then identified as a protein 
capable of dephosphorylating Akt and given the name PHLPP.  It was shown that the PP2C 
domain was responsible for the dephosphorylation at serine 473, and not at threonine 308 the 
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other activating signal for Akt [29]. Reduced expression of PHLPP was observed in several 
cancer cell lines, correlating with an increase in Akt phosphorylation. Addition of PHLPP into 
cancer cells which had low levels of the protein, showed a marked reduction in tumor growth, 
solidifying its role as a tumor suppressor [29]. Since its discovery, multiple members of the 
PHLPP family have been identified. These include  PHLPP1α [138], PHLPP1β (SCOP [29]), 
and PHLPP2. PHLPP1α and β differ in that PHLP1β is spliced such that it contains an additional 
5’ sequence, however differing roles for these two splice variants have yet to be determined 
[139]. PHLPP2 was discovered as having the same domain structure as PHLPP1 but is 
transcribed from chromosome 16q22.3, and has 50% amino acid identity [139]. PHLPP2 and 
PHLPP1 are also different in their modulation of Akt. While both isoforms target Akt1, they 
target Akt2 and 3 differently. PHLPP1 dephosphorylates Akt2, leading to a decreased activation 
of downstream targets HDM2 and GSK-3α, whereas PHLPP2 dephosphorylates Akt3, 
decreasing downstream phosphorylation of p27 [139].  These roles for the different isoforms 
allow for a more robust and specific termination of Akt and its downstream signaling pathways. 
 
Function:  
Additional roles for PHLPP in signaling pathways include an interaction with Ras, 
dephosphorylation of protein kinase C (PKC), and interaction and activation of Mst1. PHLPP1β 
was characterized as having an interaction with Ras that is mediated by its leucine rich repeat 
region. This region only binds to the subset of K-Ras that is free of guanine nucleotides and 
inhibits the downstream activation of ERK1/ERK2 [140]. Both PHLPP1 and PHLPP2 are 
capable of dephosphorylating PKC βII on its hydrophobic motif. This event causes PKC to be 
transferred to a detergent insoluble fraction, which ends PKC cycling and degrades the protein 
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[141]. Mst1 or Mammalian sterile 20-like kinase 1 is a protein involved in the apoptotic response 
and its overexpression is capable of inducing apoptosis in cells. Mst1 is capable of being bound 
by the PHLPP family members, and subsequently dephosphorylated on an inhibitory site (T387), 
activating the protein [142]. Downstream effector proteins of Mst1 include p38 and JNK which 
are responsible for mediating its apoptotic properties [143, 144]. The interaction between 
PHLPPs and Mst1 delineates a pathway by which PHLPP family members can actively induce 
apoptosis, rather than passively terminate Akt signaling.  
Regulation: 
 Expression and activation of the PHLPP family of phosphatases, may be achieved by 
multiple mechanisms. Recent research has shown that PHLPP expression is controlled by 
mammalian target of rapamycin (mTOR). Inhibition of mTOR with rapamycin resulted in a 
significant decrease in PHLPP expression [145]. While it has yet to be determined if the PHLPPs 
require phosphorylation to carry out the function of the phosphatase domain, it has been shown 
that PHLPP1 can be phosphorylated on a tyrosine residue by activated insulin receptor. It is not 
known however if this phosphorylation catalytically activates the PHLPPs, provides a docking 
site for binding with other proteins, or has some other function that enhances its activity [146]. 
Additional research has shown that FKBP51 plays a role as a scaffolding protein for PHLPP, 
allowing it to dephosphorylate Akt. Loss of FKBP51 as observed in pancreatic cancers, allows 
for increased Akt phosphorylation and subsequent tumorigenesis [147]. The inactivation or 
inhibition of the PHLPP family members may also occur by additional mechanisms. The 
PHLPPs have been shown to be held inactive by being bound to other proteins. Adenylyl cyclase 
6 (AC6) is an enzyme involved in the cyclic AMP pathway which is capable of binding to 
PHLPP2. When PHLPP2 is bound by AC6, it is inhibited and Akt phosphorylation is enhanced. 
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This inhibition is removed by stimulation with isoproterenol or forskolin, allowing PHLPP2 to 
dephosphorylate Akt [148]. Repression of PHLPP activity has also been observed to be mediated 
by elimination via ubiquitination and degradation. This degradation is mediated by β-TrCP 
containing E3 ubiquitin ligase that requires PHLPP1 to be phosphorylated. The necessary 
phosphorylation occurs on a serine or threonine residue mediated by casein kinase 1 or GSK-
3β. Because GSK-3β is inhibited downstream of activated Akt, this regulation reveals a pathway 
in which active Akt represses PHLPP degradation and forms a negative feedback loop [149].  
 The phosphatases PHLPP1 and PHLPP2 are relatively ‘new’ proteins whose regulation 
and function are not yet fully understood. Thus far, as a regulator of Akt, the expression and 
activity of PHLPP is evidenced to be tightly regulated by multiple mechanisms. Abberations in 
this regulation leading to decreases in PHLPP activity could lead to a hyperactivation of Akt, 
allowing cells to proliferate more rapidly and perhaps undergo tumorigenesis. Negative 
regulation of these PHLPP proteins by various mechanisms including repression by miRNA 
could represent a route through which arsenic exposure enhances Akt phosphorylation. 
 
     VII.      Akt Activation and Cancer 
Akt kinase: 
The serine/threonine kinase Akt was first discovered in early 1990s by three independent 
groups through screening cDNA libraries from human cell lines MCF-7, WI38 and HeLa,  [150, 
151] or isolating AKT8 retrovirus from rodent T cell lymphoma [152].  Since the similarity in 
the kinase domain to protein kinases A (PKA) and C (PKC), it was also named as protein kinase 
B (PKB).  Further studies revealed that three human gene loci encode three highly homologous 
Akt isoforms, Akt1, Akt2 and Akt3.  It is believed that each Akt isoform might have preferential 
30
activating signaling pathways and distinctive functions in cell growth, metabolism and cancer 
development [153].  Akt1 is ubiquitously expressed in a majority of tissues, whereas Akt2 is 
detected mostly in insulin-sensitive tissues, including liver, pancreas, skeletal muscle, and 
adipose tissue.  In contrast, the expression of Akt3 is largely restricted to brain and testis.  All 
Akt isoforms contain an N’-terminal pleckstrin domain (PH domain), a central kinase domail and 
a C’-terminal hydrophobic motif.  In response to extracellular stimuli, Akt1 was phosphorylated 
at the threonine 308 in the kinase domain (309 in Akt2, 305 in Akt3) and serine 473 (474 in Akt2 
and 472 in Akt3) by PI3K-phosphoinositide–dependent protein kinase (PDK1) and mTORC2, 
respectively.  Activated Akt can phosphorylate a number of downstream targets important for 
cell proliferation, apoptosis, metabolism, malignant transformation, and neoangiogenesis, such as 
FoxO3a, FoxO4, TSC2, DSK3a/b, MDM2, BAD, eNOS, IKKα, etc., some of which may contain 
Akt recognition motif R-X-R-X-X-S/T-B [154]. 
 
Activation of Akt Signaling: 
Several reports indicated that arsenic is able to activate Akt in a number of cell lines, 
which was considered as one of the key mechanisms of arsenic-induced carcinogenesis.  For 
example, a study by Zhang et al. [31] showed that arsenic activated Akt in BEAS-2B cells in a 
time dependent manner. The Activation of Akt by arsenic peaked at 4 to 8 hours, which possibly 
contributes to arsenic-induced phosphorylation of FoxO3a, but not GADD45α expression.  An 
earlier study by Souza et al. [155] suggested that arsenic induced Akt phosphorylation at both 
ser473 and thr308 in keratinocytes.  It was speculated that arsenic-induced activation of MAP 
kinase, p38, might be responsible for such an Akt phosphorylation.  In 3T3L1 cells, Akt 
activation by arsenic inhibited differentiation of these cells to fat cells by interfering with the 
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PPARγ signaling on the expression of adipogenic genes [156]. Even in some types of leukemic 
cells that are sensitive to arsenic-induced cell apoptosis, activation of Akt and the downstream 
mammalian target of rapamycin (mTOR) by arsenic were observed, which could explain the 
resistance of some patients with leukemia to arsenic treatment [32].  In addition, data from 
phosphoproteomic profiling suggested activation of Akt as well as receptor tyrosine kinases and 
MAP kinases in human small airway epithelial cells treated with either short-term or long-term 
arsenic exposure [33].  Furthermore, most recent study indicated that arsenic-activated Akt signal 
is pivotal for the release of angiogenic factors from human bronchial epithelia cell line, BEAS-
2B, and lung tumor cell line, A549 cells [157]. 
 It remains to be fully elucidated how arsenic activates Akt.  Overwhelming evidence 
suggested that Akt kinases are downstream targets of several receptor tyrosine kinases (RTK) 
that are regulated by growth factors, cytokines, and insulin [154].  In general, engagement of 
RTK with growth factors, such as EGF, PDGF, IGF-1, etc., causes tyrosine phosphorylation of 
the receptor and/or adaptor proteins, which in turn attracts binding of the p85 regulator subunit of 
the class I phosphatidylinositol 3-kinase (PI3K) to the receptor or adaptor protein through the Src 
homology 2 (SH2) domains in p85, followed by activation of the p110α kinase subunit of the 
PI3K.  Activated PI3K phosphorylates phosphatidylineositol-4,5-bisphosphate (PIP2) to generate 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), a second messenger that is capable of recruiting 
effector proteins containing a PH domain, such as PDK1 and Akt to the proximity of the cell 
membrane, enabling PDK1 to phosphorylate Thr308 of the Akt kinase.  RTK and/or additional 
intracellular signaling pathways can also activate mTORC2 complex that phosphorylates Ser473 
of Akt, resulting in full activation of the Akt kinases.  The conversion of PIP2 to PIP3 catalyzed 
by PI3K can be negatively regulated by a tumor suppressor, phosphatase and tensin homolog 
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(PTEN). In addition, the activated Akt can be inactivated by PHLPP that is able to 
dephosphorylate Ser473 of the Akt kinases.  
 As previously mentioned, exposure of cells to arsenite can activate RTK, such as the c-
src/EGFR signaling pathways [18], which very likely contributes to the activation of PI3K and 
Akt.  One possibility of arsenic-induced RTK activation is the oxidative inactivation of protein 
tyrosine phosphatases (PTPs) by the reactive oxygen species (ROS) induced by arsenic.  Several 
studies demonstrated that arsenic is able to activate NADPH oxidases to generate ROS that can 
inactivate PTPs by direct oxidizing the invariant cysteine (Cys) residue in the signature motif of 
PTPs  [158, 159].  It was shown that arsenic not only enhances expression of some NADPH 
oxidase subunits, such as p47phox and p22phox, but also induces phosphorylation and 
membrane translocation of these subunits to activate the NADPH oxidase.  Biochemical 
evidence indicates that transient activation of the NADPH oxidase causes mild and reversible 
oxidation of the PTPs by a modification of Cys with sulfenic acid.  In contrast, sustained 
activation of the NADPH oxidase will result in irreversible oxidation of the PTPs due to the 
addition of two (sulfinic acid) or three (sulfonic acid) oxygens to the Cys residue in the signature 
motif of PTPs. In addition to the classic activating signaling, arsenic-induced Akt activation 
might also be achieved by other signaling pathways, such as MAPK and STAT3 [160, 161].  
Akt Activation and Activity in Cancers: 
Accumulating evidence suggests that Akt activation or activity is altered in a number of 
human cancers or cancer cell lines.  Amplified expression of Akt1, Akt2 or Akt3 mRNA has 
been documented in various human malignancies, such as colon cancer, breast cancer, ovarian 
cancer, prostate cancer, glioblastoma, hepatocellular carcinoma, and pancreatic cancer.  In 
33
addition, activating point mutations at Akt1 or the p110α subunit of PI3K had been noted in 
some cancers.  Furthermore, some cancers exhibited functional deficiency of PTEN or PHLPP, 
the negative regulators of the PI3K and Akt signaling pathway, due to mutations, deletions or 
promoter methylation  [162].   
The cancer promoting activities of Akt family kinases are largely based on their 
regulatory roles on cell growth, cell cycle, cell survival, metabolism, migration, and 
angiogenesis.  One of the first identified functions of Akt is its role in inducing cell growth by 
increasing cell mass, which is possibly through activating mTOR complex 1 (mTORC1).  In 
response to nutrients or growth factors, Akt dependent phosphorylation of Ser939 and Thr1462 
on tuberous sclerosis complex 2 (TSC2), a tumor suppressor and inhibitor of mTORC1, 
suppresses the inhibitory function of TSC1-TSC2 complex, leading to activation of mTORC1 
and the subsequent activation of protein translational machinery for cellular protein synthesis 
[163].  The survival function of Akt in cellular responses to apoptotic stimuli is achieved by Akt-
dependent phosphorylation and inactivation of several pro-apoptotic factors, including BH3-only 
protein BAD, FoxO3a, FoxO4, caspase-9, etc.  The pro-survival or anti-apoptotic function of Akt 
might also be made through crosstalk with other signaling pathways that are important for cell 
proliferation or metabolism, such as NF-κB and MAP kinases.  It has been well-known that Akt 
or its activating signaling is critical for cell proliferation or cell cycle regulation.  A number of 
studies revealed that Akt is capable of phosphorylating Thr157 on p27kip1, an endogenous 
inhibitor of cyclin-dependent kinase inhibitor [164].  This phosphorylation prevented p27 nuclear 
translocation due to cytosolic sequestration via 14-3-3 binding of the p27 protein, leading to a 
sustained activation of the cyclin-dependent kinases and cell proliferation.  During the 
pathogenesis of tumorigenesis, formation of the new blood vessels through neoangiogenesis is 
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the key for the blood supply of the growing tumors.  In this regard, Akt dependent expression of 
hypoxia-inducible factor-α (HIF1α and HIF2α) might be pivotal for the expression and secretion 
of VEGF from the endothelial cells [165].  In addition, phosphorylation of endothelial nitric 
oxide (NO) synthase (eNOS) by Akt can promote NO production, which causes vasodilation and 
vascular remodeling during angiogenesis [166].  Taken together, it is clear that Akt activation by 
arsenic or other environmental hazards is one of the central mechanisms of carcinogenesis 
associated with environmental exposure. 
VIII. Summary: 
 The expression of miRNA has been linked to several diseases as well as normal cellular 
development and function. MiRNA expression has been intensely studied in relationship to 
cancer development and progression with the hope that miRNAs will provide insights into better 
and faster diagnosis, accurate prognosis, as well as more efficient and effective therapeutic 
strategies. Arsenic is a well known human carcinogen that, while extensively studied, its 
carcinogenic mechanisms are not fully understood. On the cell and molecular level arsenic is 
known to cause formation of reactive oxygen species, alter DNA methylation and interact with 
proteins causing aberrant kinase activation and altered gene expression. The kinases activated by 
arsenic are commonly found to be activated in cancers as well including ERK, JNK and Akt. 
While it is likely that arsenic exposure might regulate miRNA expression, it has not been well 
studied to this point. We hypothesize that arsenic exposure can influence miRNA expression 
resulting in specific miRNA changes that can control critical downstream pathways associated 
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Fig. 2. Schematic representation of miRNA biogenesis and function. Adapted from Beezhold, K. 





Fig. 3. Modulation of microprocessor function. Adapted from Beezhold, K. et al. Molecular 
Cancer 9, 134 [59] 
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The role of trivalent arsenic (As
3+
) on the regulation of the recently identified noncoding 
small RNAs, mainly, microRNAs (miRNAs), has not been explored so far.  In the present study 
we provide evidence showing that As
3+
 is a potent inducer for the expression of miR-190 in 
human bronchial epithelial cells.  The induction of miR-190 by As
3+
 is concentration-dependent 
and associated with the expression of the host gene of miR-190, talin 2, a gene encoding a high-
molecular-weight cytoskeletal protein.  The elevated level of miR-190 induced by As
3+
 is 
capable of down-regulating the translation of the PH domain leucin-rich repeat protein 
phosphatase (PHLPP), a negative regulator of Akt signaling.  Such a down-regulation is occurred 
through direct interaction of the miR-190 with the 3’-UTR region of the PHLPP mRNA, leading 
to a diminished PHLPP protein expression and consequently, an enhanced Akt activation and 
expression of vascular endothelial growth factor (VEGF), an Akt-regulated protein.  
Overexpression of miR-190 itself is able to enhance proliferation and malignant transformation 
of the cells as determined by anchorage-independent growth of the cells in soft agar.  
Accordingly, the data presented suggest that induction of miR-190 is one of the key mechanisms 
in As
3+
-induced carcinogenesis.  










Environmental or occupational exposure to arsenic, especially the trivalent inorganic 
arsenic (As
3+
), is continually a major public health concern in a number of countries worldwide, 
including the United States of America (USA) [1].  In the south-western region of the USA, As
3+
 
levels in the groundwater of some areas ranged from 680 to 1880 µg/L (~9 to 25 µM)[2].  
Several population based case-control studies suggested a strong association of As
3+
 exposure 
with small and non-small cell lung cancers [1], and other cancers [3].  It is particularly important 
to note that not only high levels of As
3+
 exposure but also low to moderate levels of As
3+
 
exposure in certain regions of the world have been linked to an increased risk of lung cancer.  
International Agency for Research on Cancer (IARC, 2004) has classified As
3+
 as a group I 
carcinogen for lung cancer.  In addition, several ecological and cohort studies also confirmed 
As
3+ 
contribution to human lung cancers [4-6].  Thus, there is an urgent need to understand how 
lower dose and sustained As
3+
 exposure causes malignant transformation of the lung cells.  
 
Previous studies by our group and others have shown that As
3+
 activated several kinases 
upstream of transcription factors, thereby, regulating the expression of genes important for cell 
cycle transition and cell proliferation [7-9].  Recently, a group of genes that encode small 
noncoding RNA, including microRNA (miRNA), small nuclear RNA (snRNA), small nucleolar 
RNA (snoRNA), and piwiRNA, have been identified.  In this study, we explored the effect of 
As
3+
 on the expression of miRNAs.   
 
Human miRNA genes are either located in intergenic areas or in introns of known genes.  
Under the regulation of RNA polymerase II, primary miRNA (pri-miRNA) is transcribed and 
then subjected to processing by the RNase enzyme Drosha in the nucleus to form precursor 
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miRNA (pre-miRNA) with hairpin loops about 70 nucleotides in length.  The pre-miRNA is then 
exported to the cytoplasm by the nuclear membrane protein Exportin-5 and further processed by 
the RNase Dicer to generate mature miRNA.  Following association with the miRISC protein 
complex, one strand of the mature miRNA binds to its complementary 3-UTR region of the 
target mRNA to repress translation or promote degradation of the target mRNA, depending on 
the degree of complementary binding [10].   
 
Emerging evidence suggests that many miRNAs play a pivotal role in malignant 
transformation and carcinogenesis of cells.  Examples of this include the overexpression of miR-
155 in pancreatic cancer [11] and lymphomas [12], as well as an increase of miR-221/222 in 
prostate cancer [13]. Increases in miR-155 expression have been attributed to activation of NF-
κB [14] through JNK[15] and AP-1 transcription factors [16]. Increases in miR-155 expression 
are linked to repressing apoptosis through Tumor protein 53 induced nuclear protein 
1(TP53INP1) [11], enhancing growth and cell plasticity by targeting RhoA [17],  and enhancing 
survival by targeting FOXO3a [18].  Human miRNA-190 is derived from an intron region of the 
talin 2 gene on chromosome 15.  The proteins of the talin family include talin 1 and talin 2.  
They share several highly conserved domains, such as the rod domain and the FERM domain, 
that are important for interaction with F-actin, integrin, PIP5KI isoforms, and focal adhesion 
molecules [19, 20].  Earlier data indicate that inhibition of miR-190 decreased growth of HeLa 
cells without an overall change in the apoptotic caspase activity [21].  An additional study shows 
that the level of miR-190 was increased in granulocytes from patients with primary 
myelofibrosis [22].  These results suggest a role for miR-190 in regulating cell cycle or 
proliferation rate.   
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In the present report, we demonstrate that As
3+
 is a potent inducer of human miR-190, 
correlating with an increased accumulation of its host gene product, talin 2 protein.  Through 
repressing expression of the PH domain leucin-rich repeat protein phosphatase (PHLPP), its 
target gene encoding a negative regulator of Akt signaling, increased level of miR-190 is able to 
enhance the activation of Akt, leading to an increased expression of vascular endothelial growth 
factor (VEGF).  Overexpression of miR-190 itself is able to enhance proliferation and 
anchorage-independent growth of the cells in soft-agar.  Induction of miR-190, therefore, may 






Cell culture and reagents:  
BEAS-2B cells were purchased from ATCC (Manassas, VA) and seeded in 6-well plates 
at a density of 5 × 10
5
 cells per well.  Cells were cultured in DMEM medium supplemented with 
5% FBS for approximately 48 hours before treatment with arsenic chloride (As
3+
) (Sigma, MO) 
for 6-12 hours (unless otherwise specified). Cells were lysed with TRIzol reagent (Invitrogen, 
CA) according to manufacturer’s instructions for total RNA isolation and real-time RT-PCR 
experiments.  Antibodies against talin 2, β-catenin, PHLPP, TP53INP1, phospho-Akt, and non-
phospho-Akt were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) or Abcam, 
(Cambridge, MA).  ELISA kit for the detection of VEGF was purchased from Thermo Scientific 
(Rockford, IL).  Dual-luciferase assay reagents were purchased from Promega (Madison, WI). 
 
Cloning and analysis of miR-155/BIC promoter:  
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The full-length promoter for miR-155/BIC from -2000 to +127 was cloned from 
commercially purchased human genomic DNA. The promoter region was amplified using 
upstream primer 5’-gatcgctagcacgttcagattccacagct-3’ and downstream primer 5’-
CTGAAAGCTTGGCGTCCCTGCCACGTTCAA-3’. The product of approximately 2130 bp 
was excised from an agarose gel and purified using the QIAquick gel extraction kit following the 
manufacturer’s instructions. The PCR product was inserted into the TOPO XL PCR product 
cloning vector from Invitrogen and large scale isolation of the vector was done following the 
manufacturer’s protocol. The vector with PCR product insert was sequenced to check for proper 
cloning. The cloning vector plasmid and a PGL3 basic luciferase vector were double digested 
with NHE1 and HindIII restriction enzymes to insert the promoter region into the luciferase 
vector using T4 ligase. This ligated vector was then used to transform bacteria for amplification 
and isolation followed by double digestion to check for proper product insertion. 
 
Western blotting:  
Total cellular proteins were prepared with NuPage LDS sample buffer (Invitrogen, 
Carlsbad, CA) containing 50 µM DTT.   The cell lysates were run on 6% SDS-PAGE gels and 
then transferred to PVDF membranes (Invitrogen, CA). Membranes were first probed with the 
primary antibodies at a dilution of 1:2000.  The secondary antibody with AP tag was then 
applied at a dilution of 1:5000.   Densitometry analysis of the Western blotting data was 
performed using a Molecular Biosystems scanner (San Diego CA). 
 
Real-Time RT-PCR:  
The microRNA array was performed using the Cancer MicroRNA qPCR Array with 
QuantiMir
TM
 from System Biosciences (Mountain View CA) according to the manufacturer’s 
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instruction.  RNA was isolated from untreated cells as well as cells treated with 20 µM As
3+
 for 6 
hours using either TRIzol reagent or a MirVana kit from Ambion (Austin TX).  The real-time 
PCR primers and probes for the detection of talin 2 mRNA were designed using Roche online 
ProbeFinder program (http://www.universalprobelibrary.com) by selecting Automatically Select 
an intron spanning assay and G6PD as the preferred reference gene.  The designated amplicon 
will be specific for talin 2 mRNA only without contamination of the genomic DNA sequences.  
The primer sequences are: left primer, 5’-TGGTCAAATCGGCCTCAG-3’; right primer: 5’-
GACCACTGTCCGTCGTCTG-3’.  Probe #49 was used for the talin 2 real-time PCR.  
Expression of some individual miRNAs was also analyzed using TaqMan MicroRNA Assays 
from Applied Biosystems (Foster City, CA).  Reverse transcription and real-time steps were 
performed according to the manufacturer’s specifications from total RNA isolates.  Either miR-
30c or snoRNA U47 was used as the endogenous control for all real-time PCR experiments of 
miRNAs.   
 
Transfection of the cells with miRNA mimic:   
To validate the role of miR-190 on its target mRNAs, BEAS-2B cells (1 × 10
5
/ml) were 
seeded in 6-well tissue culture plates and transfected with 50 nM pre-miR negative control 
(mock), miR-190 mimic or 100 nM anti-miR-190 (miR-190In) in triplicates using a reverse 
transfection procedures as suggested by the manufacturer.  The Pre-miR™ miRNA Starter Kit 
that contains chemically modified pre-miR negative control, pre-miR-190 mimic and pre-miR-
190In were purchased from Ambion (Austin, TX).  The pre-miR negative control used in mock 
transfection is a pre-miRNA molecule with random sequence that does not target any known 
mRNA in the human cells.   The transfected cells were first cultured in serum-free medium at 
37
o





 were added 12 h before the end of the culture.  Protein levels of potential miR-190 targets 
were determined by Western blotting as described above. 
 
Reporter vector construction:  
To construct a luciferase reporter vector for the talin 2 promoter, the genomic DNA 
encompassing the 1095 base pairs human talin 2 promoter region were amplified with PCR 
primers: left primer, 5’-ATCGGCTAGCCACCATGCCAGGCTAATTTT-3’, Right primer, 5’-
CAGTCTCGAGACTCGACACGCATCGTACAC-3’.  The left and right primers designed to 
amplify the region from genomic DNA had the restriction enzyme sites for NheI and XhoI 
included, respectively, to aid insertion of the cloned region into the vector.  The talin 2 promoter 
fragment was then cloned into the pGL3-basic vector from Promega (Madison, WI).   
 
For the construction of the PHLPP 3’-UTR miRNA-targeting reporter vector, the 
genomic DNA containing a 911 base pairs region of the human PHLPP 3’-UTR was amplified 
with left primer, 5’-GATCGAGCTCCAAGAGTCTCCCAGGCTCAC-3’, and right primer, 5’-
GCTAAAGCTTTCCATTTGTGCATTCTGCTT-3’. For the purpose of deleting the miR-190-
binding site in the 3’-UTR region of the PHLPP mRNA, an additional left primer with sequence 
5’-GTCAGAGCTCATGTAAAGACAAAGAACAAAAGGTTTA-3’ was introduced in a 
separate PCR reaction, which generates a deleted 3’-UTR by removing the sequence containing 
the binding site of miR-190.  The amplified fragments were cloned into the pMIR-REPORT 
vector (Ambion, Austin, TX) utilizing the SacI and HindIII restriction enzyme sites.  Chemically 
competent E. coli (Invitrogen, Carlsbad, CA) were transformed with the vectors following the 
manufacturers recommendations. DNA sequencing was performed on the purified vectors to 
confirm proper insertion of the fragments.   
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Reporter gene activity assay:  
The indicated reporter vectors were transfected along with a pRL-TK Renilla luciferase 
vector for normalization into BEAS-2B cells in 24 well tissue culture plates using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA), at concentrations of 200 and 10 ng/well, respectively, and 1.56 
µl of the transfection reagent in a total volume of 500 µl.  After 12 hours 500 µl of DMEM 
supplemented with 5% FBS was added and the cells were incubated for an additional 12 hours.  
Following appropriate treatments or additional co-transfections with miR-190 oligos, a Dual 
Luciferase Reporter assay (Promega, Madison, WI) was performed according to the 
manufacturer’s specifications.  
 
Generation of stable cell lines:  
Stable cell lines overexpressing either miR-190 or a control oligo were generated by 
transfecting miRNASelect pEP-hsa-miR-190 and pEP-miR null expression vectors (Cell Biolabs, 
San Diego CA) into BEAS-2B cells using the same general protocol as the luciferase reporter 
gene assay. The transfected cells were subjected to selection by puromycin at 1 µg/ml for 3 days.  
 
Cell proliferation and carcinogenic transformation assays:  
Control and miR-190 stably expressing cells were seeded into a 96-well plate at 5 x 10
3
 
cells/well, cultured for 16 hours followed by serum starvation for 12 hours.  An assay for 
proliferation was then performed using Cell Titer 96 AQueous One Solution Cell Proliferation 
Assay (Promega, Madison WI) according to the manufacturer’s specifications. The plate was 
then read at 490 nm at 1, 2, 3, and 4 hour time points.  Carcinogenic transformation of the cells 
was determined by seeding the cells in soft-agar.  Briefly, the stably transfected cells were 
suspended in a 0.33% agar solution above a 0.5% agar layer containing 2- mercaptoethanol, and 
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penicillin/streptomycin in wells of 6-well plates.  The plates were incubated at 37 
o
C and 5% 
CO2 in a humidified incubator without feeding for 21 days. The colonies were counted and 
imaged on days 14 and 21.  
 
Enzyme-linked immunosorbant assay (ELISA):  
The protein concentrations of VEGF in supernatants from BEAS-2B cells receiving 
various treatments were determined using a DuoSet ELISA development system (R&D systems, 
Minneapolis MN). The cells were transfected with the pre-miR-190 or pre-miR-190In oligos as 
described earlier. The supernatants were collected and the ELISA was performed according to 
the manufacturer’s specifications. The supernatants were either diluted 1:1 or not diluted before 
incubation with the ELISA plate. Visualization was achieved using appropriate volumes of 
solution A and solution B from the Substrate Reagent Pack (R&D systems, Minneapolis MN). 
The reaction was quenched with sulfuric acid and then read on a plate reader with a wave length 
of 450 nm. 
 
Statistics:   
Both SigmaPlot 9.0 and Microsoft Excel were used in statistical analyses for the 




Effects of arsenite on miR-155 expression:  
Environmental or occupational exposure to As
3+
 poses a great risk of developing multiple 
types of cancer including cancers of the lung, skin, liver, and bladder.  Little is known about the 
effect of As
3+





 is the deregulation of miRNA, especially those oncogenic miRNAs.  Changes in 
miR-155 expression are related to tumorigenesis in epithelial cells, and its expression is 
controlled by transcription factors known to be induced by arsenic. We hypothesized that miR-
155 may play a role in arsenite-induced carcinogenesis and began to characterize the effect that 
As
3+
 might have on either transcription or biogenesis of miR-155.  To test this hypothesis, we 
cloned the promoter region for BIC/miR-155 and constructed a reporter vector by inserting the 
cloned promoter region into the upstream of the firefly luciferase gene.  During the course of 
cloning and construction of reporter vectors, a study was published, which indicates that a role 
for AP-1 but not NF-κB in the activation of miR-155 transcription and expression (16).  Thus, 
we obtained these reporter vectors which were subject to deletion or mutation of the NF-κB and 
AP-1 sites in the promoter region (Fig. 1A).  The promoter activity was determined by 
transfection of these vectors into the BEAS-2B cells followed by treatment of the transfected 
cells with As
3+
.  The results from these experiment showed that deletion of the region from -
2000 to -1494 that contains 3 NF-κB binding sites enhanced the arsenic-induced luciferase 
activity (Short), indicating that these 3 NF-κB  sites are dispensible for the miR-155 promoter 
activity in response to As
3+
.  An additional possibility is that this region might contain 
inhibitory elements that negatively regulate the promoter activity.  Site-directed mutation of the 
down-stream NF-κB site at position -1221 to -1211 also had no effect on the As
3+
-induced 
promoter activity (comparing Short to delta κB Short).  In contrast, deletion of the AP-1 site at 
position -107 to -100 completely abolished the promoter activity (Fig. 1C), which is in 




To further determine whether As
3+
 induces increase of the mature miR-155 in the BEAS-
2B cells, we next measured the levels of miR-155 by real-time PCR using RNAs from the cells 
treated with or without As
3+
.  Intriguingly, several experiments failed to detect changes of miR-
155 in the cells treated with As
3+
 (Fig.2), which possibly indicates that As
3+
 might negatively 
regulate the processing of mature miR-155. 
 
Microarray of miRNA expression: 
We revealed that As
3+
 induces miR-155 promoter activity but failed to induce mature 
miR-155 (Figs. 1 & 2).  To determine whether As
3+
 is able to regulate other miRNAs, we next 
profiled miRNA expression using Cancer MicroRNA qPCR Array that contains 95 different 
miRNAs.  Total RNA used in this analysis was isolated from the bronchial epithelial cell line, 
BEAS-2B, exposed to 20 µM As
3+
 for 6 hours.  The array showed an up-regulation of 67 
miRNAs as well as a down-regulation of 28 other miRNAs (Fig 3A).  Among the up-regulated 
miRNAs by As
3+
, the highest miRNAs induced are the miR-1-1 and miR-190.  A 4-6 fold 
induction of miR-1-1 and miR-190 by As
3+
 was noted (Supplement Table 1).  The capability of 
As
3+
 on the induction of miRNAs in this array was additionally supported by the parallel up-
regulation of miRNAs within miRNA clusters that share the same transcriptional unit, such as 
the miR-106-363 cluster (miR-92, miR-106a and miR-19a, indicated by arrows in Fig. 3) and the 
miR-17-92 cluster (miR-17-3p, miR-17-5p and miR-20a, indicated by arrow heads in Fig. 3).  Of 
the upregulated miRNAs, miR-190 was an attractive candidate for follow-up study because of its 
involvement in cell growth and proliferation [21].   
 
To validate the array data, we next performed real-time RT-PCR using total RNA 
isolated from BEAS-2B cells treated with increasing concentrations of As
3+
 for 12 hours.  A 
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concentration-dependant increase of miR-190 was seen in the cells treated with As
3+
 (Fig. 3B).  
As
3+
 at concentrations of 10, 15 and 20 µM induced a 2-, 3- and 7-fold increase of miR-190 
expression in the BEAS-2B cells, respectively.  Moreover, in addition to BEAS-2B cells, we also 
observed induction of miR-190 by As
3+
 in other two different cell lines, A549 lung cancer cell 
line (Fig. 3C) and SAEC, the primary human small airway epithelial cell line (Supplement Fig. 
S1).  A 3 fold induction of miR-190 was noted in SAEC cells treated with lower concentrations 
of As
3+




 induces miR-190 through activating talin 2 gene.  
Noncoding RNAs, including miRNAs, are transcribed either from intergenic loci or 
intronic DNA of genes.  A database search for the genomic context surrounding the miR-190 
using the online Ensemble genome information system [23] revealed that miR-190 is located on 
chromosome 15 within intron 52 of the talin 2 gene (Fig. 4A).  The talin family proteins, 
including talin 1 and talin 2, are important molecules for the spreading and mobility of the cells 
by regulating the function of integrins and the assembly of the stress fibers [24].  To determine 
whether or not an increase in expression of miR-190 correlates with expression of the talin 2 
mRNA and protein, real-time RT-PCR and Western blotting were performed (Figs. 4B and 4C).  
In agreement with the data for miR-190 expression, As
3+
 induced talin 2 mRNA accumulation in 
a concentration-dependent manner (Fig. 4B), which correlated with an increased levels of the 
talin 2 protein (Fig. 4C).  The peak induction of the talin 2 mRNA occurred in the cells treated 
with 20 µM As
3+
 for 12 h (Fig. 4B).  Semi-quantification of the Western blotting data by 
densitometry scanning showed that As
3+
 at concentrations of 10 and 20 µM induced a 1.5- to 2-




To further assess the capability of As
3+
 on the induction of the talin 2 gene, a luciferase 
reporter gene activity assay was conducted by using a reporter vector containing the proximal 1 
kb region of the talin 2 promoter.  Transfection of BEAS-2B cells with the talin 2 reporter gene 
and followed by exposure to As
3+
 showed a concentration dependant induction of talin 2 
promoter activity (Fig. 4D).  All of these data clearly indicate that the expression of miR-190 in 
response to As
3+
 is associated with the expression of its host gene.  These results also suggest 
that regulation of miR-190 by As
3+
 is very likely at the level of transcription.  
 
 miR-190 targets PHLPP:  
As
3+
 is an established human carcinogen and some miRNAs have been previously 
demonstrated as oncogenic miRNAs that can suppress expression of the tumor suppressors or 
activate cell growth signaling [25].  The information available on the role of miR-190 in human 
carcinogenesis is currently very limited.  We postulate that miR-190 may be partially responsible 
for the carcinogenicity of As
3+
 by affecting certain oncogenic signals.  In order to identify 
potential targets of miR-190 we adopted a computational approach by using several of the 
available prediction algorithms based on evolutionary conservation of target sites across species, 
including miRDB [26, 27], PicTar [28] and Targetscan [29].  One limitation of this approach is 
that each of these algorithms predicts hundreds of possible targets for miR-190 or other 
miRNAs.  To circumvent this problem, we focused on the targets important for cell proliferative 
or pre-survival signals that were predicted by all of these programs.  Among the predicted 
candidate targets, 3’-UTRs of human PH domain and leucine-rich repeat protein phosphatase 
(PHLPP) and tumor protein 53-induced nuclear protein 1 (TP53INP1) contained regions that 
matched the seed sequences of miR-190.  The predicted miR-190 binding sites are found 223 nt 
and 217 nt downstream of the stop code for PHLPP (Fig. 5A) and TP53INP1 (supplement Fig. 
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S2A) mRNAs, respectively.  The binding site of miR-190 is well conserved among PHLPP 
mRNAs from other species, including monkey, rat, mouse, horse and chicken, which is 
indicative for the importance of miR-190 on the regulation of PHLPP (Fig. 5A).  PHLPP is 
known to target phosphorylated serine473 specifically for dephosphorylation and inactivation of 
Akt kinase, leading to an increased apoptotic potential, and thereby causing tumor suppression 
[30].  We had previously demonstrated that As
3+
 is able to activate Akt in BEAS-2B cells [31].  
Accordingly, it is very likely that As
3+
-induced Akt activation is achieved through the 
downregulation of PHLPP by miR-190, leading to a sustained Akt activation and an increase in 
cell growth and proliferation, resulting in cell transformation.  Western blotting examining the 
level of the PHLPP protein in the cells treated with As
3+
 clearly indicated a concentration-
dependent repression of the PHLPP protein (Fig. 5B), suggesting a potential link between  As
3+
-
induced miR-190 and Akt activation. 
 
Transfection of the cells with miR-190 precursor suppresses PHLPP expression:  
To verify above observation indicating that As
3+
-induced expression of miR-190 can 
repress the translation of the PHLPP protein, the cells were directly transfected with a mock 
transfection, miR-190, and miR-190In, respectively.  As depicted in Fig. 3C, PHLPP protein 
levels were reduced in the cells transfected with the miR-190 by 60-70% relative to the mock-
transfected cells (Fig. 5C, lanes 1 & 2).  No inhibitory effect of the miR-190In on PHLPP was 
observed (Fig. 5C, lane 3).  Again, treatment of the cells with As
3+
 decreased expression of the 
PHLPP protein (Fig. 5C, lane 4).  
 
To confirm that miR-190-mediated repression of PHLPP expression is achieved through 
interacting with the potential miR-190 binding site in the PHLPP 3’-UTR region, the entire 3’-
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UTR of PHLPP mRNA was cloned downstream of a luciferase gene in the pMIR-REPORT 
vector.  The BEAS-2B cells were co-transfected with this reporter vector, pRL-TK Renilla 
luciferase vector, and miR-190 or miR-190In.  We observed that the co-transfection of the miR-
190 suppressed the luciferase activity of the vector with the PHLPP 3’-UTR by about 40% (Fig. 
5D).  In contrast, the miR-190In did not show inhibition on the PHLPP 3’-UTR reporter activity.  
Moreover, deletion of the miR-190 binding site within the PHLPP 3’-UTR abrogated the 
repressive ability of the miR-190 on the reporter gene activity (Fig. 5E), demonstrating 
specificity of the target sequence for PHLPP.  Thus, these data provide strong evidence 
suggesting that As
3+
-induced miR-190 is crucial for the downregulation of the PHLPP protein.  
    
Expression of miR-190 enhances Akt phosphorylation and VEGF production: 
Having found that miR-190 represses expression of PHLPP, a negative regulator of Akt 
kinase by dephosphorylation of the serine 473 (Ser473)-phosphorylated, but not threonine 308 
(Thr308)-phosphorylated,  Akt [30], we investigated Ser473 phosphorylation of Akt in the cells 
treated with 20 µM As
3+
 in the presence or absence of overexpressed miR-190 or miR-190In.  
Western blotting assays using antibody specific for Ser473 phosphorylation of Akt was 
performed followed by a densitometry quantification of Akt phosphorylation.  As indicated in 
Fig. 6A, 10 µM As
3+
 activated Akt in a time-dependent manner with a peak occurring at 8 h, as 
judged by the Ser473 phosphorylation of Akt.  Although decreased after As
3+
 treatment for 12 
and 20 h, the activation of Akt at these time points is still evident (compare lanes 4 & 5 to lane 1, 
Fig. 6A).  In an additional experiment using cells treated with As
3+
 for 12 h in the absence or 
presence of miR-190, both As
3+
 and miR-190 induced Akt phosphorylation notably (Fig. 6B, 
comparing lanes 2 and 5 to lane 1).  Akt activation by As
3+
 was substantially enhanced in the 
67
  
cells overexpressing miR-190 (Fig. 6, lane 6).  In contrast, this effect was not seen in the cells 
transfected with the miR-190In (Fig. 6B, lanes 3 and 4). 
 
To determine if the effect of miR-190 on Akt phosphorylation has any downstream 
effects, an ELISA experiment for the expression of VEGF, a protein whose expression is known 
to be induced by the activation of Akt [32], was performed. Results from the ELISA show that 
both As
3+ 
and miR-190 are able to induce expression of VEGF.  Combination of As
3+
 and miR-
190 further enhanced VEGF induction (Fig. 6B, lane 6, the bottom panel).  Enforced expression 
of miR-190In, has very marginal effect on the basal VEGF expression (Fig. 6B, bottom panel, 
lane 3).  Furthermore, miR-190In appears to be unable to potentiate As
3+
-induced VEGF 
expression (lane 4).  These results indicate that miR-190 is indeed able to stimulate Akt 




miR-190 enhances cell proliferation and carcinogenic transformation:  
The observations that miR-190 induced by As
3+
 represses PHLPP and consequently 
activates Akt imply that this miRNA is an important regulator of critical cellular events 
associated with carcinogenesis, such as proliferation and transformation.  To determine if over 
expression of miR-190 leads to substantial changes in cell proliferation, colony formation and/or 
other properties associated with malignant transformation and carcinogenesis, stably transfected 
BEAS-2B cell lines were generated by expressing miR-190 or a control vector.  The stable miR-
190 overexpressing cells exhibited an approximate nine-fold increase of miR-190 expression 
compared to control transfected cells (Fig. 7A).  A substantial enhancement of Akt activation in 
the cells stably expressing miR-190 was observed (Fig. 7B).  To determine how miR-190 
expression affects cells, we next measured cell growth by a MTS-based cell proliferation assay.  
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As depicted in Fig. 7C, cells stably expressing miR-190 showed a significant increase in 
proliferation either in the absence or presence of different concentrations of As
3+
.  In agreement 
with the results from transient transfection, VEGF expression was increased in the stable miR-
190 expression cells (Fig. 7D).  To directly determine whether overexpression of miR-190 
enhances malignant transformation of the cells, we next performed anchorage-independent cell 
growth assay by seeding the cells in soft agar.   Colony formation by the cells stably expressing 
miR-190 was substantially enhanced.  The number of colonies was increased more than 50% 
when compared to cells stably expressing the control miRNA (Fig. 7E).  Remarkably, cells 
stably expressing miR-190 formed large colonies (pointed by white arrows, Fig. 7F), whereas 
cells stably expressing the control-miRNA formed only small aggregates of the cells (Fig. 7F).  







tumorigenic as demonstrated in both experimental animal and epidemiological 
studies of human populations in some specific environmental or occupational settings.  The 
detailed mechanism of As
3+
-induced malignant transformation of the cells, however, remains to 
be fully established.  A number of intracellular signaling pathways can be perturbed in response 
to As
3+
 exposure, including redox balancing, kinase activation, transcription factor activity, DNA 
damage repair, and cell cycle.  All of these pathways are either directly or indirectly linked to 
cell growth, apoptosis and transformation.  The regulatory role of As
3+
 on the expression and 
function of miRNA has not been explored yet.  The discovery in this report that As
3+
 induces 
miR-190 expression, therefore, may provide an additional mechanistic insight into As
3+ 
exposure 




Unlike other well-studied miRNAs, such as let-7, miR-155 and miR-21, the function of 
miR-190 is largely unsubstantiated.  In HeLa cells, inhibition of miR-190 by anti-sense RNA 
compromised cell growth without effect on cell apoptosis [21].  The level of miR-190 was 
significantly increased in the granulocytes isolated from patients with primary myelofibrosis 
(PMF) relative to granulocytes from normal subjects [22].  PMF is the rarest and most severe 
form of the Ph¯  myeloproliferative disorders (MPDs), including PMF, polycythemia vera (PV) 
and essential thrombocythemia (ET).  Since PMF is characterized by aberrant proliferation of the 
megakaryocytes in the bone marrow, it is believed that such a disorder is very likely due to 
deregulation of the stem-cell niche or deficiency in stem-cell differentiation.  Indeed, a recent 
study using human embryonic stem cells and differentiated embryoid bodies indicated a 
significant up-regulation of miR-190 expression in embryoid bodies and embryonic stem cells 
relative to the adult cells [33].  Furthermore, an association of miR-190 overexpression with 
clonal malignant transformation has been observed in hematopoietic stem cells [34], suggesting 
potential linkage of miR-190, cancer stem cells and cancer development.    
 
Additional evidence suggesting the role of miR-190 played in cancer development has 
recently been provided by miRNA profiling in pancreatic cancer tissue samples and pancreatic 
cancer cell lines [35].  Real-time PCR data indicate that miR-190 was one of the eight most 
highly expressed miRNAs in pancreatic cancer, whereas its expression in normal pancreatic 
tissues was hardly detectable.  An average of 21-fold increase of miR-190 was noted in 17 
pancreatic cancer tissues relative to the case-matched normal pancreatic tissues.  Similarly, miR-
190 had been previously implicated as a signature miRNA in B cell chronic lymphocytic 
leukeminas (CLL) [36].  As compared to the normal CD5
+
 B cells, the level of miR-190 in CLL 
70
  
was substantially increased.  It was believed that this increase in miR-190 expression in CLL is 
possibly a result of genomic rearrangement because the host gene of miR-190, talin 2, is located 
in the common fragile sites that are prone to breakage and rearrangement in cancers.   Increased 
expression of miR-190 has most recently been demonstrated in several other types of tumors, 
including bladder cancer [37], breast cancer [38], lung cancer [39], a subset of HBV positive 
hepatocellular carcinoma [40], and colorectal cancer [41].  Intriguingly, a miR-190 homolog has 
also been identified in the Bombyx mori (silkworm) genome, and its expression has been 
implicated as an important process for the normal development of Bombyx mori [42].   All of 
these observations clearly indicate that miR-190 is a cell growth-regulating miRNA. 
Overexpression of miR-190, thus, is oncogenic. 
 
miR-190 is an intronic miRNA whose gene is located in the 52
nd
 intron of the talin 2 
gene.  The observed association of miR-190 expression with its host gene, talin 2, in the present 
study was complementarily supported by observations indicating coordination between talin 2 
gene transcription and miR-190 biogenesis in neuron [43].  In mouse or rat hippocampal 
neurons, activation of the µ-opioid receptor by its agonist, fentanyl, reduced both talin 2 gene 
transcription and miR-190 expression in a manner of extracellular signal-regulated kinase 
(ERK)-mediated phosphorylation of YY1.  Phosphorylation of YY1, a transcription factor, 
resulted in an impairment of YY1 association with and activation on the talin 2 promoter, leading 
to a decreased transcription of talin 2 gene and consequently, reduced biogenesis of miR-190.  It 
is still unclear how intronic miRNAs are transcribed and processed.  Several lines of evidence 
implicated interdependency of pre-mRNA splicing and Drosha-dependent pri-miRNA processing 
[44], whereas other studies revealed a possible mutual competition between pre-mRNA splicing 




Emerging evidence shows that oncogenic miRNAs contribute to the initiation and 
progression of cancer largely through regulating the expression of genes involved in the control 
of cell lineage development, cell proliferation, cell apoptosis, and kinase activation in the cells.  
For example, both miR-17 and miR-20a are able to negatively regulate expression of the E2F1 
transcription factor to alter the dynamics of cell cycle progression [46].  The potential targets of 
miR-190 identified in the present report, PHLPP and TP53INP1, have been previously 
demonstrated as important regulators for protein kinase Akt signaling and cell apoptosis, 
respectively [30, 47].  PHLPP is a PH domain-containing serine phosphatase, which specifically 
dephosphorylates phosphorylated Ser473 of Akt and inactivates Akt, leading to cell apoptosis 
[30].  It has been well-established that full activation of Akt requires both Thr308 
phosphorylation by PDK1 and Ser473 phosphorylation by mTORC 2 or DNA-PK.  Accordingly, 
loss of PHLPP expression will prolong the Ser473 phosphorylation and activation of Akt.  
Indeed, in some breast and colon cancers, it was believed that loss of PHLPP expression is 
responsible for the sustained Akt activation, tumorigenesis and metastasis [48, 49].  Thus, 
induction of miR-190 by As
3+
 and the consequent PHLPP downregulation by miR-190 can 
provide the cells with a self-sustaining growth signal due to loss of a negative regulator of the 
Akt kinases.  This may also partially explain observations indicating that As
3+
 is a potent inducer 
of Akt activation in bronchial epithelial cells and fibroblast cells as reported by ourselves and 
others [31, 50].  Downregulation of TP53INP1 by As
3+
-induced miR-190, on the other hand, 
would cause the cells to be insensitive to pro-apoptotic signals.  All of these effects of miR-190 
induced by As
3+
, therefore, may be causatively important in malignant transformation and 




In summary, we have provided the first evidence showing that As
3+
 is capable of 
inducing miR-190 expression associated with an appreciable protein accumulation of its host 
gene, talin 2.  Elevated miR-190 in response to As
3+
 is responsible for the downregulation of 
PHLPP and TP53INP1, two important tumor suppressors.  Reduced PHLPP expression will 
consequently cause a prolonged or potentiated Akt activation and expression of its downstream 
targets, such as VEGF, leading to either a malignant transformation of the normal cells or 
tumorigenesis of the transformed cells. We believe that these discoveries may shed new light on 
the carcinogenic mechanism of environmental and occupational As
3+
 exposure.  Further 
experiments are in progress to determine additional authentic targets of the miR-190 and how 





 To further support the hypothesis that arsenite is capable of inducing the expression of 
miR-190, small airway epithelial cells (SAEC) were exposed to increasing concentrations of 
arsenite for 48 hours (Fig. S1). An increase in expression of miR-190 was observed indicating 
that this effect is not limited to transformed cell lines, giving support for the hypothesis. 
TP53INP1 is a p53 inducible protein which takes part in the induction and regulation of 
p53-mediated apoptosis [47].  A decrease in the expression of TP53INP1 in tumor tissue has 
been documented [51, 52].  Re-expression of TP53INP1 is known to be tumor suppressive [11]. 
TP53INP1 is indicated to be a potential target of miR-190 by in silico analysis.  An appreciable 
concentration-dependent inhibition of the TP53INP1 in the cells by As
3+
 was noted (Supplement 
Fig. S2).  Accordingly, induction of miR-190 by As
3+
 will repress the expression TP53INP1, 
which will consequently weaken the tumor suppression potential and enhance carcinogenesis. 
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As an additional control for testing the effect of miR-190 on the pmiR-REPORT-PHLPP 
vector, we experimented on the effect of miR-190 on the cells transfected with pMIR-REPORT 
empty vector.  No inhibitory effect of miR-190 on this empty reporter vector was observed 
(Supplement Fig. S3). 
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Figure 1: MicroRNA-155/BIC promoter activity. A. A depiction of the four different promoter 
luciferase reporter vectors used. B. Average normalized luciferase activity expressed in relative 
luciferase units of the two wild type vectors and the NF-kB knockout vector in response to 
increasing concentrations of arsenite. C. Average normalized luciferase activity of the short wild 









Figure 2: Exposure to arsenite does not alter miR-155 expression in BEAS-2B cells. 
The expression level of mature miR-155 was measured by real-time PCR in BEAS-2B cells after 











































Figure 3:  As
3+
 regulates expression of miRNAs. 
using Cancer MiRNA Panel shows expression of miRNAs after As
miRNAs in the miR-106-363 cluster; arrow heads indicate miRNAs in the 
Data are representative of three experiments.  
time RT-PCR was performed using total RNA extracted from the BEAS
indicated concentrations of As
3+
 







A. A real-time RT-PCR-based miRNA array 
3+




 induces expression of miR
-2B cells treated with the 
for 12 h.  Data are means ± SD of five experiments.  
 
 







Figure 4:   Talin 2 expression in response to As
3+
.  A. Schematic diagram of the talin 2 gene and 
pre-miR-190 within the intron 52 region of the talin 2 gene.   Underlined sequences indicate the 
sequences that form pre-miR-190 duplex through complementarily association of the inverted 
repeat region.  The asterisk (*) indicates passage strand of the miR-190 duplex.  B. Real-time 
RT-PCR analysis of talin 2 mRNA production in response to As
3+
.  C.  Talin 2 protein was 
induced by a 12 h-exposure of the cells with As
3+
 at the indicated concentrations.  A loading 
control was made by Western blotting using antibody against β-catenin.  N.s.: non specific 
bands.   The bottom numbers show semi-quantification of the talin 2 protein expression by 
densitometry.   Data are representative of 3 experiments.  D. The talin 2 promoter reporter gene 
activity is activated by As
3+
 exposure. Data is normalized by calculating the ratio between 





Figure 5:  miR-190 targets PHLPP.  A.  Schematic diagram of the miR-190 binding site at the 
3’-UTR of PHLPP mRNA.  Lower panel shows alignment of the predicted miR-190 binding 
sites to 3-UTR of PHLPP from different species (Homo sapiens, Macaca mutatta, Rattus 
norvegicus, Mus musculus, Eguus caballus, and Gallus gallus).  B.  Western blotting shows 
concentration-dependent reduction of the PHLPP protein in the cells treated with As
3+
.  C. 
Overexpression of miR-190 downregulates PHLPP.  The BEAS-2B cells were mock transfected, 
or transfected with a miR-190, miR-190In, or treated with 20 µM of As
3+
.  The protein level of 
PHLPP was determined by Western blotting. D. Overexpression of miR-190, but not miR-190In, 
down-regulates the activity of the PHLPP 3’-UTR reporter gene.  E. Overexpression of miR-190 




Figure 6: Overexpression of miR-190 enhances As
3+
-induced Akt phosphorylation and VEGF 
generation. A.  BEAS-2B cells treated with 10 µM As
3+
 for the indicated hours and Akt 
phosphorylation at Ser473 was determined by Western blotting.  The bottom panel shows 
relative levels of Akt phosphorylation as determined by the ratio of 33hosphor-Akt vs non-
phospho-Akt that were determined by densitometry scanning of 3 independent Western blotting 
experiments. B. BEAS-2B cells were transfected with the miR-190 and miR-190In, respectively.  
Phosphorylation of Akt at Ser473 was analyzed by Western blot.  The bottom panel shows 
VEGF expression following miRNA transfection and As
3+
 exposure by ELISA. Data shown is 











Figure 7: Stable expression of miR-190 enhances cell proliferation and carcinogenic 
transformation.  A.  The levels of miR-190 in the cells stably transfected with a control miRNA 
and miR-190 were determined by real-time PCR.  B.  Levels of Akt activation in the stably 
transfected cells were determined by Western blotting using antibody against Ser473-
phosphorylated Akt (up panel) or the non-phospho-Akt (bottom panel). The numbers at the 
bottom of the lower panel indicates ratios of Phospho-Akt vs non-phospho-Akt.  C.  The stably 
transfected BEAS-2B cells were cultured for 16 h followed by As
3+
 treatment with the indicated 
concentrations for an additional 12 h.  Cell proliferation was determined as described in the 
“Materials and Methods”.  D.  VEGF levels were determined by ELISA in the stably transfected 
cells.  E.  Quantification of the colony numbers of the stably transfected cells in soft agar.  F. 
Anchorage-independent growth of the stably transfected cells was determined by the colony 
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formation in soft agar.  White arrows indicate large colonies formed by the cells stably 


























upregulated fold change Downregulated 
fold 
change 
miR-190  5.887 miR-134  0.245 
miR-1-1 4.508 miR-136  0.260 
miR-19a+b 2.576 miR-198  0.263 
miR-29a+b+c 2.574 miR-206  0.401 
miR-93 2.308 miR-223  0.402 
let-7-family 2.274 miR-145 0.433 





miR-30b 2.111 miR-188  0.476 
miR-218 2.083 miR-215 0.488 
miR-10b 2.002 miR-150  0.497 














miR-26a 1.867 miR-202 0.825 
miR-137  1.860 miR-106b 0.823 
miR-24  1.845 miR-200b 0.885 
miR-219 1.820 miR-488 0.923 
miR-132 1.740 miR-205  0.932 










miR-23a 1.674     
miR-195  1.639     
miR-21  
1.635     
miR-194  1.626     
miR-30c  1.626     
miR-151 
1.621     
miR-27a+b 1.620     
miR-191  1.609     
miR-95  1.589     
miR-224  1.574     
87
  
miR-15b  1.577     
miR-146a 1.553     
miR-20a 1.530     
miR-126  1.530     
miR-155  1.516     
miR-101-1 1.482     
miR-30a-3p 1.463     
miR-22  1.458     
miR-210  1.455     
miR-128b  1.451     
miR-183 1.428     
miR-204  1.424     
miR-185  1.417     
miR-142-3p 1.396     
miR-196a 1.380     
miR-133a 1.249     
miR-181c 
1.245     
miR-125b 1.242     
miR-214  1.231     
miR-17-3p  1.217     
miR-16 1.216     
miR-221  1.215     
miR-192  1.200     
miR-92 1.161     
miR-181b 
1.136     
miR-125a 1.136     
miR-18a 1.113     
miR-199a+b 1.110     
miR-107  1.096     
miR-135b 1.086     
miR-186  1.083     
miR-200c 




























Figure S2. miR-190 targets TP53INP1. A. Schematic diagram shows the miR-190 binding site at 


























RT-PCR for miRNA Target Identification:  













When considering the changes in expression of miRNA in disease states or in response to 
various stimuli the important next step is to identify downstream targets of the affected miRNA. 
While knowledge of a change itself is of some interest, uses of this information are limited 
without understanding of the impact of this change. In order to identify miRNA targets, much 
bioinformatic work has been done in the way of designing algorithms used to predict potential 
miRNA:mRNA pairs. These predicted targets must then be verified by various in vitro and in 
vivo approaches including the use of reporter vectors and site-directed mutagenesis. The usage of 
these algorithms is a hit-or-miss method of target identification, though the algorithms that have 
been designed continue to improve. One method is the usage of learning algorithms that verify 
potential miRNA-target interactions.  The calculations might be altered to more accurately 
reflect proven relationships. While this method is helpful, other approaches should be developed 
which can more accurately and quickly identify miRNA targets. Such advancement would 
potentially aid in the quick identification of ‘higher value’ targets for possible therapeutic 
intervention.  
 
 While thinking about miRNA targeting the 3’UTR of an mRNA target, it is not difficult 
to view this interaction as similar to primer annealing duing a PCR reaction. In light of this 
thought, one could conceivably try to identify miRNA targets by using miRNA mimic primers to 
amplify mRNA targets. This approach is somewhat problematic, and issues arise that lead to 
multiple approaches for target identification, or a variety of outcomes. One approach might be to 
try and prime the RT-PCR reaction with the miRNA mimic primer alone. This approach relies on 
assumption that the mimic primer could bind to an mRNA, synthesizing a long un-ended product 
during the RT-step. The primer then would have to bind to some other downstream site based 
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upon some random priming (Fig.1A). This method would require manipulation of the 
concentrations of the PCR reaction so that it would require as stringent pairing. This would 
probably be necessary for any reaction utilizing miRNA mimic primers, as these would contain 
multiple mismatches with an mRNA target. If by chance a product was obtained by the PCR 
reaction, several verification steps would be necessary to be sure the miRNA:target interaction 
was genuine. A variation of this method was published in 2008 which described using 
endogenously bound miRNAs in cell extracts as reverse transcriptase primers to create a pool of 
miRNA bound mRNAs [1]. A gene specific primer and a primer against an adapter oligo ligated 
to the 5’ end of the miRNA were then used to identify genes that were targeted by miRNA, the 
specific miRNA and its binding site within the mRNA. One of the major drawbacks of this 
technique is that it requires that you first have a gene of interest and then determine its regulatory 
miRNA(s), instead of having a miRNA of interest and finding the gene(s) it regulates. The major 
positive for this technique is that it maintains the secondary structure of the mRNA and enhances 
the specificity of miRNAs for their targets by using cell extracts for the first RT reaction. By 
utilizing this technique the number of false positives should be cut down dramatically.   
 
A second approach could utilize a specific upstream primer for a predicted mRNA target 
for a miRNA of interest (Fig. 1A). The usage of target prediction algorithms would still be 
necessary, and the results would still need to be verified, leaving this approach as not much more 
than an additional verification for in silico prediction that given current technologies may not be 
necessary. A third approach that would be significantly more complicated would utilize tagged 
miRNA mimics for specific miRNA target precipitation followed by PCR verification. This is a 
method that has already been described in part but is not commonly practiced. The previously 
described method performs a miRNA ‘pull-down’ using deoxygenin labeled miRNAs to isolate a 
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pool of mRNA targets. This pool is then sub-cloned and sequenced to determine the putative 
targets for the miRNA [2]. This method was confirmed to be useful in the identification of hand2 




 In order to determine if miRNAs were capable of priming an RT-PCR reaction on total 
RNA from cells, multiple mimic primers were used including mimics for miR-21, miR-155, let-
7a, let-7b, and miR-1. The PCR reactions were set up and run as detailed in the materials and 
methods section, and the products were run on an agarose gel. Due to the imperfect 
complementarity of miRNA-target binding, the stringency of the PCR reaction was tweaked to 
allow for greater mis-pairing of the primers to enhance the number of potential targets by adding 
magnesium sulfate to the PCR reaction. A trial was run using the let-7a primer for 3 different 
concentrations of magnesium sulfate including 1.5 (standard), 3, and 6 mM, where the 3 mM 
concentration yielded the best results. After multiple attempts the miRNA mimic primers were 
capable of priming PCR products visible on the agarose gel (Fig. 1B). Because miR-21 had the 
brightest and most easily discernable bands, the 4 brightest bands were cut, purified and cloned 
into a cloning vector for sequencing, the results from which suggest that bands 1 and 4 (from top 
to bottom) were amplifying the same gene, and interestingly this happened to be overlapping 
sequences. A BLAST search for the amplified sequences in the GenBank showed that the PCR 
products have a near perfect alignment with the MT-CO1 sequence with the exception of the 
mis-paired sites from the imperfectly complementary miRNA-mimic primer binding sites (fig. 
2). The sequenced PCR products (bands1 and 4) also shared an upstream priming site referred to 
as priming site 1 on the anti-sense strand where the miRNA-mimic primer bound to the region 
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encompassing the start codon. The miR-21 mimic primer also bound to two downstream sites on 
the sense strand creating two products, one ~ 200 base pairs in length (priming site 2) with the 
other (priming site 3) ~500 base pairs. It is interesting to note that the mimic primer binding site 
was backward compared to typical miRNA binding sites with the ‘seed sequence’ located on the 
3’ end of the miRNA rather than the 5’ end. Additionally the miRNA mimic binding sites are 
located within the coding region of the gene, not in the typically observed 3’UTR or even in 
more rare cases the 5’ UTR. However some precedent does exist for miRNAs binding to the 
coding region [3].  
 
The gene that was targeted by the miR-21 mimic primers is a mitochondrial protein 
known as mitochondrial cytochrome c oxidase subunit 1, MT-CO1, or COX1. If this interaction 
were to be verified, it would be the first time to our knowledge that an endogenous mammalian 
miRNA was demonstrated to target a gene produced from mitochondrial DNA. An emerging 
phenomenon within the field of cancer research is that a shift in the major metabolic pathways 
could be a potent driver of cancer progression [4]. Under normal aerobic conditions a cell uses 
glycolysis to create energy and pyruvate that then goes to the mitochondria to produce energy 
and carbon dioxide. It is becoming more evident that cancer cells rely more heavily on glycolysis 
with the pyruvate being used as an intermediate for other cellular products instead of being used 
by mitochondria [5, 6].  Cytochrome c oxidase is a major component of the electron transport 
chain that catalyzes the reduction of oxygen to water, and MT-CO1 is part of its catalytic core 
[7].  A decrease in MT-CO1 expression, as often observed in cancers, by overexpression of miR-
21, thus, may induce the shift from normal aerobic metabolism to “aerobic glycolysis”. Thus, in 
addition to its known targets such as PTEN and PDCD4 [8, 9], which are tumor suppressors, 
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miR-21 may additionally target MT-CO1, enhancing tumorigenesis by altering metabolic 
pathways together with repressing proteins known to inhibit growth.  
 
Some preliminary work suggests that arsenic is capable of inducing miR-21 expression 
(Table 1 in chapter 2). As previously discussed, miR-21 is a known oncogenic miRNA.  
Overexpression of this miRNA is observed in many solid tumors, and an increase in expression 
in response to arsenic may mediate its carcinogenic effect. If miR-21 could be shown to repress 
MT-CO1 expression as well as its other known targets in response to arsenic, this could be an 
additional mechanism by which arsenic induces cancer.  
 
Materials and Methods: 
 
Reverse-transcriptase PCR for target identification:  
microRNA-mimic primers were purchased from Operon. The sequences are as follows; 
Let-7b 5’-UGAGGUAGUAGGUUGUGUGGUU-3’, miR-155 5’-
UUAAUGCUAAUCGUGUAUAGGGGU-3’, miR-1 5’-
UGGAAUGUAAAGAAGUAUGUAU-3’, miR-21 5’-UAGCUUAUCAGACUGAUGUUGA-
3’. The Access quick RT-PCR system from Promega was used to run the PCR reactions. The 
general conditions for the PCR reaction are as follows; 25 µl 2x master mix, 1 µl polyT primer 
(100 mM), 1 µg total RNA from BEAS-2B cells, 3 µl mimic primer, 3 µl additional MgSO4 (25 
mM stock; 3 mM final), and water to a total of 50 µl. The RT-PCR cycling was set up with the 
RT-step starting at 45 degrees for 45 minutes followed by 95 degrees for 2 minutes. The PCR 
cycling that followed was 95 degrees for 30 seconds, 50 degrees for 30 seconds, and 70 degrees 




Potential target cloning:  
The PCR products were visualized on an agarose gel. Those bands chosen for sequencing 
were excised from the gel and purified using the QIAquick gel extraction kit from Qiagen 
following the manufacturer’s instructions. The purified PCR product was then cloned into the 
TOPO TA cloning vector purchased from Invitrogen according to the manufacturer protocol. 
Following successful cloning, the vectors including the inserts were sequenced using the generic 
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Figure 1. Reverse-transcriptase PCR for miRNA target identification. A. Depicts two of the 
possible mechanisms for PCR amplification of miRNA targets using miRNA mimic primers. 
Top, miRNA mimic primer binds to sites on the sense and antisense strand of the resulting 
cDNA molecule. Bottom, a primer specific for the antisense strand of a potential target is utilized 
for gene amplification. B. The miRNA mimic primers prime PCR products visible on an agarose 
gel. The closed arrows from the gel picture indicate which bands represent the amplified sections 
of the MT-CO1 gene. The open arrows indicate where each priming site is located in the MT-
CO1 sequence. The sequence and imperfect complementarity for each binding site is provided.  
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Figure 2. Sequence alignment of the sequencing results for PCR product 4 (priming site 2) with 


























Environmental or occupational exposure to many naturally and non-naturally occurring 
chemicals, minerals, industrial products and by-products are known to cause cancer in humans. It 
is unsurprising that the majority of cancers are carcinomas or cancers of epithelial origin as the 
epithelial layers represent the primary site of contact for chemical exposure and are thus more 
susceptible to cancer formation in this regard. Cancers of the lung and bronchus represent the 
majority of cancers diagnosed yearly within the US, the leading cause of which is exposure to 
first or second-hand tobacco smoke. An additional cause of lung cancer, more so in developing 
nations than in the US is exposure to arsenic via contaminated drinking water or exposure by 
inhalation. The inhalation of arsenic in the form of arsenite is typically an occupational hazard 
involved in mining or smelting activities. Arsenite is a well-known toxin classified as a class 1 
cancer-causing agent by the World Health Organization. Paradoxically arsenic trioxide is used as 
a treatment for some cancers including promyelocytic leukemia (PML). This brings to light a 
dynamic where high dose arsenite is toxic to cells, whereas long-term exposure to low dose 
arsenite is tumorigenic. Due to the nature of long-term exposure, teasing out all of the details of 
how arsenite causes cancer has been difficult and the mechanisms are not fully understood. The 
small RNA molecules known as miRNA are now recognized as important regulators of cell 
function. These molecules play important roles in control over normal cell function, development 
and disease. Changes in expression of miRNA are easily induced, and are capable of aiding or 
inducing disease.  We aimed with this work to shed further light on the mechanism of arsenite-






Data summary and significance 
Arsenite induces changes in miRNA expression: 
 The ability of arsenite to induce changes in miRNA expression levels was in some ways a 
foregone conclusion for this study. Due to the ability of arsenite to alter the activity of 
transcription factors across varying concentrations and exposure times it stood to reason that 
miRNA expression levels would change. At the outset of this study only one other report had 
been completed indicating a role for arsenite, sodium arsenite for this specific study, in the 
expression of miRNA [1]. This report however reported ‘global’ increase in miRNA expression, 
which was partially contrary to our findings. Since this paper, several additional reports have 
been published showing a role for arsenite in altering miRNA expression. Typically these reports 
involve arsenic trioxide as a therapeutic for various cancers [2-4]. One study however indicates a 
role for miR-181b and miR-9 in arsenic induced angiogenesis [5]. Neo-angiogenesis is an 
important event during carcinogenesis, and this study indicates that miRNA may play an 
important role in arsenic induced malignancies. For this study the expression of miRNA-155 was 
studied in response to arsenic due to its potential for transcriptional control by arsenite. While 
real-time PCR studies for the mature mRNA were unsuccessful at detecting a change, promoter 
reporter vectors for the miR-155/BIC promoter were. These experiments indicated that arsenite 
could activate the promoter region. This conflict in results may indicate that in addition to 
activating transcription, arsenite has some effects downstream which interfere with miRNA 
processing. Additionally, there could be potential that the BEAS-2B cells contain some attribute 
which maintains expression of the mature miR-155 at a low level. 
 
 The array performed for this study showed that exposure of BEAS-2B cells to arsenite 
both increased and decreased the expression of several miRNAs. Of these miRNAs one that was 
104
most interesting was miR-190 due to its potential to alter Akt signaling, a known outcome of 
arsenic exposure. The induction of expression by arsenite was confirmed using real-time PCR 
and the expression of miR-190 was correlated with the expression of its host gene, talin 2 
(TLN2), which is in agreement with the previous report indicating that miR-190 and Talin 2 are 
produced from the same transcript [6]. This correlation suggests that the changes in miR-190 
abundance are occurring at the transcriptional level.  
 
Arsenic induced miR-190 represses PHLPP expression: 
 To determine the effect of increased miR-190 expression we utilized multiple algorithms 
that predict potential miRNA targets. The most compelling target for miR-190 was PHLPP. This 
phosphatase was recently discovered and is known to target S473 on Akt for dephosphorylation 
[6]. The 3’UTR region for PHLPP was cloned downstream of a luciferase reporter gene. 
Transient transfection of a miRNA precursor readily repressed expression of the reporter. 
Deletion of the miR-190 binding site removed the inhibitive effect of the precursor, indicating 
that this binding site is the true target for miR-190 within the PHLPP transcript, and that PHLPP 
is a functional target of miR-190. As a tumor suppressor gene, repression of PHLPP expression 
in response changes in miR-190 downstream of arsenite presents an interesting scenario for 
arsenic-mediated carcinogenesis. Arsenite is a known inducer of cell stress, and at higher 
concentrations, induces cell death. If the concentration is low enough an enhanced activation of 
Akt could allow cells to escape apoptosis and survive even after cellular damage from the arsenic 
has occurred.  
 
MiR-190 enhances Akt phosphorylation downstream of arsenite exposure: 
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One of the major findings from this study is that arsenite induced Akt phosphorylation 
and activation is enhanced by miR-190 expression through repression of PHLPP. The enhanced 
or prolonged Akt signal may be a factor that helps drive cellular survival during cell stress. The 
enhanced survival allows for the transformative effects of arsenite to occur instead of apoptosis. 
Akt has a multitude of cellular targets involved in enhancing survival, growth, cell cycle 
progression, and protein synthesis. Akt enhances cell survival by activating XIAP [7], an 
inhibitor of apoptosis, as well as MDM2 [8] a p53 inhibitor. Akt inhibits the apoptotic mediators, 
such as Bim, Bad [9] and Bax [10], potentially allowing cells to survive during various apoptotic 
stimuli. Akt can enhance cell cycle and growth by inhibiting cell cycle inhibitors such as p27Kip 
[11], and Myt1, a wee1 family member [12]. Akt also inhibits GSK-3, a Cyclin D1 inhibitor 
[13]. Akt activates PFK-2 [14] which increases glycolysis, and PIP5K [15] which increases 
glucose transport. The increased metabolic potential is helpful for cell growth and division. Akt 
enhances protein synthesis that is necessary for cell cycle progression by activating mTOR and 
S6. Akt activates mTOR by inhibiting the TSC1/TSC2 inhibitory complex as well as PDCD4, 
another mTOR inhibitor [16, 17].  
 
 Active Akt has long been recognized as an important signaling protein involved in 
enhancing or inducing tumorigenesis. More recent studies continue to support this finding 
highlighting its importance as a potential therapeutic target. One such study analyzes the role of 
the Akt isoforms in K-Ras mediated lung tumorigenesis [18]. The results from this study showed 
that Akt1 but not Akt2 or Akt3 were involved in K-ras induced carcinogenesis. Indeed deletion 
of Akt1 prevented the formation of tumors, whereas deletion of Akt3 led to increased tumor 
multiplicity and size. This finding indicates that Akt1 and Akt3 have opposing roles in 
tumorigenesis suggesting that a specific Akt1 inhibitor would be a better therapeutic option than 
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one that targeted all three isoforms like those that are currently used for clinical development 
[19]. Interestingly the different isoforms of PHLPP target the various Akt isoforms differently. 
While both PHLPP1 and PHLPP2 target Akt1, only PHLPP2 targets Akt3 for dephosphorylation 
[20]. PHLPP1 and PHLPP2 are transcribed from different chromosomes and have different 
3’UTR regions, and as a result in silico analysis suggests that miR-190 targets only PHLPP1 and 
not PHLPP2. Inhibition of miR-190 would enhance abundance of PHLPP1 and not PHLPP2 
leading to decreased phosphorylation of Akt1 and not Akt3. This indicates that miR-190 may be 
a useful therapeutic tool in that it may modulate Akt1 but not Akt3 which are suggested to have 
opposing roles. While modulating miRNA function may be therapeutically less potent than 
directly targeting Akt1 itself, its potential benefits may still remain.  
 
 Activation of Akt is known to induce downstream signaling pathways such as induction 
of VEGF. The current report indicates that miR-190 enhanced Akt activation by arsenic is also 
capable of increasing VEGF expression, a known outcome of arsenic exposure [21-23]. 
Expression of VEGF is strongly linked with tumor vascularization, enhancing tumor invasion 
and metastasis as well as inducing epithelial cell growth [24].  VEGF is a common target for 
cancer therapy across a wide range of tumor types [25]. Induction of VEGF expression by 
arsenic through miR-190, thus, may be able to explain in part the ability of arsenic to induce 
tumor formation in epithelial cells.  
 
Overexpression of miR-190 enhances colony formation: 
 The most compelling result from this research is that stable overexpression of miR-190 in 
BEAS-2B cells led to an increased number of colonies formed as well as an increase in colony 
size. These data were accompanied by an increase in cellular proliferation as well Akt 
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phosphorylation and VEGF expression. The increase in colony formation and size indicates that 
overexpression of miR-190 enhances the likelihood that cells will continue to proliferate when 
growing in a context that normally inhibits proliferation. An increase in tumor growth even in the 
face of anti-proliferative signals (contact inhibition with low serum levels) is the most common 
indicator of cellular transformation and tumorigenesis. That miR-190 overexpression causes cells 
to exhibit these characteristics is a strong indication that this miRNA is an oncogenic miRNA.  
 
RT-PCR for target identification: 
 Verifying the mRNA targets of miRNAs is crucial to determining the roles of individual 
miRNAs within cells.  Current methods for ascertaining miRNA targets are based upon in silico 
analysis which is subject to much error, or requires that you start with a protein of interest before 
moving to a targeting miRNA. In order to design an inexpensive and quick method for 
identifying potential miRNA targets, a reverse-transcription approach was adopted. We found 
that miRNA mimic primers could be used to amplify sections of mRNA if the stringency of the 
PCR reaction was adjusted properly. Upon sequencing the products amplified by miR-21 mimic 
primer, MT-CO1 was identified as a potential target. This target has yet to be verified by western 
blotting or other means upon manipulation miR-21 expression, however it may have some 
meaningful implications as discussed in the previous chapter. Due to the limited number of 
products observed for each miRNA mimic primer used, this method does not produce a 
comprehensive look at potential miRNA targets as each miRNA is likely to target many mRNAs. 
Adjustment of the PCR reaction may be necessary for the individual mimic primer to increase 
the number of potential targets but also attempt to minimize the number of false positives. 
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Although a great potential of errors remain, this method may have some promise as a quick and 
inexpensive tool for miRNA target identification. 
 
Using miRNAs as therapeutics: 
 The utilization of miRNAs as therapeutics has the potential to revolutionize the way 
diseases are treated. In many cases medicine is only able to treat the symptoms but not the 
underlying disease. If miRNAs can be successfully manipulated, protein expression that causes 
the disease phenotype can be changed. In therapeutics, miRNAs are categorized into a class 
called antisense oligonucleotides or ASOs, which includes other short oligos such as siRNAs.  
The most significant challenge facing this group of therapeutics is uptake and delivery. 
Modification of oligos including the addition of 2’-O-methyl ribose sugars and conjugation to 
cholesterol allows for uptake into cells [26]. Additional modification includes the use of locked 
nucleic acids or LNAs. These are nucleosides which contain a methylene bridge to keep them in 
the ideal conformation for Watson-Crick binding. LNA oligos have a higher affinity for target 
mRNA, and repress their targets more quickly and efficiently [27]. Therapeutic oligos can be 
delivered directly to the target. This delivery increases bioavailability and minimizes off tissue 
targeting, but is restricted to tissues like skin, eyes, mucous membranes and solid tumors [26]. 
Where specific targeting is not possible, ASOs can be packaged into pegylated liposomes or lipid 
nanoparticles that contain cationic lipids allowing for first uptake and then release of the 
packaged ASOs once in the cell [28]. Once in the cell the ASO will carry out its intended effect 
after any requisite processing.  
 A few therapeutic trials utilizing ASOs have shown success thus far. The most promising 
ASO undergoing trials thus far is an LNA-antimiR against miR-122. This ASO is capable of 
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targeting miR-122 specifically in the liver, reducing replication of Hepatitis C Virus that is 
dependent on miR-122, as well as reducing total plasma cholesterol [29]. This ASO is currently 
undergoing phase 2 clinical trials for hepatitis C infection as wells as cancer and inflammatory 
diseases [26].  
 
Future studies: 
 Future studies proceeding from this work include a number of potential avenues of 
research. One important area that is currently underway is the determination of what signaling 
pathways and transcription factors are responsible for the induction of miR-190 expression by 
arsenite. This information would be useful if modulation of miR-190 expression would prove to 
have therapeutic potential. Instead of trying to alter miR-190 levels by targeting the molecule 
itself, modulation of some upstream regulator may achieve the desired effect. Preliminary 
experiments have shown that ERK kinase may be responsible for the induction of miR-190 
expression. Activation of ERK through the MAP kinase cascade leads to the activation of the 
transcription factor MYC. The miR-190/TLN2 promoter contains multiple MYC binding sites 
and could potentially be responsive to them. A second transcription factor which may be 
responsible for activating miR-190 expression is AP-1, a downstream target of JNK. The miR-
190/TLN2 promoter also contains AP-1 binding sites including conserved ‘canonical’ sites.  
Arsenic is known to activate both of these transcription factor signaling pathways and they are 
critical for mediating the proliferative effects of arsenic. 
 As mentioned earlier, there are differences in the roles of the varying isoforms of Akt in 
cellular function as well as differences in how the different PHLPP isoforms regulate Akt 
phosphorylation. Reports indicate that active Akt3 has effects that counteract the other isoforms, 
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and the only PHLPP isoform which targets Akt3 is PHLPP2. It is highly unlikely that miR-190 
targets PHLPP2 due to the lack of miR-190 binding site(s) in the 3’-UTR region, therefore it 
would be of considerable interest to determine whether modulation of the Akt isoforms by 
manipulation of miR-190 would yield significant results that would be therapeutically useful. A 
comprehensive study analyzing the effects of miR-190 overexpression or repression on the 
phosphorylation of the various Akt isoforms paired with a targeted therapeutic model to 
determine if miR-190 modulation would yield better results than a pan-Akt inhibitor, thus, would 
shed light on this issue.  
An additional area of research of considerable interest would be to tease out exactly the 
role miR-190 has in arsenite induced cancers and/or other malignancies. In the study of cancer 
caused by arsenite exposure it appears that miR-190 expression is a transient phenomenon. 
While in the presence of arsenite, cells produce more miR-190, which will enhance Akt 
phosphorylation and the subsequent survival signal. This survival signal enhanced by transient 
miR-190 expression may be enough to overcome cellular death signals and allow for DNA 
alterations leading to cell transformation. Some preliminary data has shown that BEAS-2B cells 
transformed by long-term low-dose exposure to arsenite do not exhibit persistent overexpression 
of miR-190. It would be of interest to generate a miR-190 knockout mouse or cell line to test 
how readily these animals or cells undergo transformation in response to arsenite or other 
transformative stimuli. If it could be shown that miR-190 knockout animals are more resistant to 
carcinogenesis, it could be of significant worth to pursue miR-190 as a therapeutic target. 
Further research could also be performed on the ability of miR-190 to enhance expression 
of VEGF. Increased expression of VEGF has severe consequences for increased angiogenesis for 
tumor growth. Tumor cells are known to produce high levels of VEGF to enhance the growth of 
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new blood vessels and vascularize the solid tumor [30]. Once vascularized, the tumor can 
increase in size, and is more likely to become metastatic. It would be of significant interest to 
determine whether miR-190 plays a role in the ability of tumor cells to produce VEGF and 
recruit endothelial cells to the tumor causing neo-vascularization. Therapeutic targeting of miR-
190 may be capable of reducing VEGF expression and inhibit tumor growth through a decreased 
vascularization and ensuing necrosis.  
 Under the broader study of arsenic-induced miRNA expression, our lab has generated 
some preliminary data suggesting that arsenite induces the expression of miR-21. Interestingly 
the expression of this miRNA also has implications for the activation of Akt in response to 
arsenite, which involves down-regulation of PTEN, a negative regulator of the upstream 
activating signaling for Akt, by miR-21 [31]. Also involved in the Akt pathway is another known 
miR-21 target, the PDCD4 tumor suppressor [32]. Akt directly phosphorylates and inhibits 




 Since shortly after the discovery of miRNA, changes in miRNA expression have been 
linked to disease states, with the hypothesis that the miRNAs are causative rather than being a 
result of the disease. The expression of miRNA is now established as important regulators of 
cellular function and they are being targeted for therapeutic intervention. The research in the 
current study set out to understand if arsenic could regulate the expression of miRNAs, and 
whether these miRNAs might play a role in arsenic-induced carcinogenesis. The results from this 
study indicate that arsenite indeed does regulate the expression of miRNAs associated with 
neoplastic transformation or tumorigenesis. Specifically, the expression of miR-190 in response 
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to arsenite and the enhanced Akt activation downstream of PHLPP repression, provide a 
mechanism by which arsenite could cause diseases. This pathway also presents a potential 
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MicroRNAs (miRNAs) are a class of small, noncoding RNAs critically involved 
in a wide spectrum of normal and pathological processes of cells or tissues by fine-tuning 
the signals important for stem cell development, cell differentiation, cell cycle regulation, 
apoptosis, and transformation.  Considerable progress has been made in the past few 
years in understanding the transcription, biogenesis and functional regulation of miRNAs.  
Numerous studies have implicated altered expression of miRNAs in human cancers, 
suggesting that aberrant expression of miRNAs is one of the hallmarks for 
carcinogenesis.  In this review, we briefly discuss most recent discoveries on the 







MicroRNAs (miRNAs) are endogenously synthesized small non-coding RNAs 
that regulate gene expression by interfering with protein translational machinery and/or 
inducing degradation of target mRNAs [1].  Since the discovery of miRNAs, much effort 
has been made to understand the mechanisms by which miRNAs are synthesized and 
involved in cell lineage development and human diseases, especially, cancer.  It is 
imperative that scientists continue to delineate how the biogenesis of these miRNAs is 
controlled by the cellular processing machinery, so that one may better understand how to 
modulate their expression or function as it contributes to a unique disease state. Recent 
research shows the involvement of additional proteins that modulate the function of the 
miRNA processing machinery, the Drosha processing complex, or microprocessor. This 
article reviews these new findings and discusses the potential for targeting these 
regulatory pathways in cancer therapy. 
 
MicroRNA biogenesis:  
It has been well-established that the biogenesis of microRNAs (miRNAs) 
involves three step-wise processes, including transcription of primary miRNAs (pri-
miRNAs) from the miRNA genes [2], partially processed precursor miRNAs (pre-
miRNAs) in nuclei [3] and the mature miRNAs that were generated in the cytoplasm 
(Fig. 1).  Pri-miRNA is  typically a large RNA polymerase pol II-derived transcript 
whose tertiary structure forms stem loop structures. The stem loop is  cleaved off by the 
microprocessor machinery, Drosha complex, to form ~60-100  nucleotide long pre-
miRNA, which is  further processed into ~22 nucleotide long mature miRNAs by Dicer, a 
RNase III enzyme, following translocation from the nuclei to cytoplasm [4].  
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After successful cleavage, the pre-miRNA is bound by exportin-5 in a ran-GTP  
dependant manner and exported from the nucleus [5-7]. Binding of pre-miRNA by 
exportin-5 is dependent upon the stem of the miRNA, requiring a length of 16-18 base 
pairs, and alterations in the 3’ overhang will  affect  the efficiency of exportin-5 
binding[8]. Interestingly, reduced binding of exportin-5 by reduction of the protein itself 
or alteration in the miRNA structure causes a reduced expression of the mature miRNA, 
without buildup of pre-miRNA in the nucleus [5]. This suggests that exportin-5 may play 
a protective role during miRNA transport to the cytoplasm [8]. Once in the cytoplasm, 
the pre-miRNA is released from exportin-5 after the hydrolysis of GTP, and is free to be 
processed further.  
 
In the cytoplasm, pre-miRNA undergoes the next step of processing mediated by 
Dicer to produce the mature miRNA. The  RNase III enzyme, Dicer,  was found to cleave 
RNAs into ~ 22 nucleotide products [9-11]. This cleavage occurs in an ATP independent 
manner, through which the loop structure and 3’ overhang are removed [12].  
Recognition and correct cleavage of the pre-miRNA are determined by the different 
domains of Dicer.  Dicer contains a PAZ domain which recognizes the 3’ end of the pre-
miRNA, and the rest of the molecule acts as a molecular ruler directing the RNase III 
domains to cleave the 3’ overhang and the loop structure to generate the mature miRNA 
[13]. After cleavage, one strand of the miRNA duplex is preferentially incorporated into 
the RISC complex. The selection of one strand over the other is based upon 
thermodynamic properties of the duplex, and the strand with the less thermodynamical 
stability at the 5’ end is usually selected [14]. The mature miRNA bound to RISC  then 
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associates with an Argonaute protein, most commonly Ago2, and directs binding of the 
RISC complex to partially complementary sites in the 3’-UTRs of targeting mRNAs [15].  
 
Previous observations suggested that the specificity of miRNA is determined by 
the sequence complementarity between bases 2-8 on the 5’ end of the miRNA, termed the 
seed sequence, and the target mRNAs [16, 17]. A recent study appears to oppose this 
seed sequence pairing mechanism, and identifies binding and repression of mRNA by 
several “seedless” miRNA-mRNA duplexes [18]. In a microarray study for proteins 
down regulated by miR-24 expression, it was observed that multiple genes whose 
expression was reduced do not have predictable target sequences. Using an algorithm that 
does not require a seed match, it was further confirmed that the miR-24 targeting 
sequences are indeed within the 3’ UTRs of the repressed genes [18].   
 
There are multiple mechanisms by which miRNAs downregulate gene expression, 
some of which are still in controversy. These mechanisms have been reviewed in-depth 
elsewhere [19]. Briefly, mRNAs have been observed to be repressed by three major 
processes including endonucleolytic cleavage, mRNA degradation by deadenylation, and 
inhibition of translation initiation.  Similar to siRNA-mediated mRNA degradation, the 
endonucleolytic cleavage of mRNA by miRNA requires perfect or near perfect 
complementarity between miRNA and the target mRNA. If such a condition is satisfied, 
proteins within the RISC complex are then able to cleave the mRNA, leading to its 
degradation and silencing [20]. This gene silencing process has been shown to occur in 
multiple organisms including mammals. Of note however, this mechanism of gene 
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regulation rarely occurs in mammalian cells because nearly all miRNA-mRNA 
interactions have significant mismatches [17, 21-23].  
 
Inhibition of translation initiation is another widely studied mechanism of 
miRNA-induced gene silencing.  In 2005 Pillai et al. found that a miRNA-targeted 
reporter mRNA sedimented with small polysomes in HeLa cells, which indicates the 
repression occurred  at translation initiation. In the same publication, they also showed 
that reporter constructs which are not dependant on the 7-methyl guanosine cap structure 
did not undergo repression, and suggested that miRNPs are capable of binding to the cap 
structure [24]. A motif was later found within AGO2 that was indeed capable of binding 
to the 5’ cap structure of mRNA, which could then compete with eIF4E that is necessary 
for initiation of translation [25]. 
 
Cellular localization is another mechanism by which miRNA might mediate 
repression of mRNA translation. There is evidence suggesting that some miRNP-bound 
mRNAs localize to p-bodies within the cytoplasm. The  p-bodies are cytoplasmic foci 
that contain mRNAs that are not actively undergoing translation. The p-bodies also 
contain proteins that are responsible for mRNA degradation [26].  Several observations 
suggest that mRNAs within the p-bodies are being repressed by miRNA that are co-
localized in these foci.  However, a detailed mechanism by which the repression occurs 
has yet to be fully determined.  In addition, the deadenylation of mature mRNA has been 
implicated as a mechanism by which miRNAs are able to repress protein translation 
within the p-bodies.  It was believed that GW182, a protein important for deadenylation 
of mRNAs, localizes in p-bodies and is able to interact with AGO1. This interaction leads 
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to recruitment of decapping complexes and subsequent degradation of the miRNP-bound 
mRNA [27-29]. 
 
Microprocessor and pri-miRNA processing: 
The pri-miRNAs transcribed from miRNA genes usually exhibit a size of several 
thousands of nucleotides long, whereas the size of mature miRNAs is only about 22 base 
pairs [30].  As briefly mentioned earlier, the generation of mature miRNA, encoded by 
either an intron of protein-coding gene or intergenic non-coding transcription unit, 
requires two sequential endonucleolytic cleavages by RNase III enzymes.  A nuclear 
protein, Drosha, is the first enzyme to catalyze such processing.  It is believed that 
Drosha is able to cleave intronic pri-miRNA without interference with the splicing of the 
precursor mRNA (pre-mRNA) [31].  There is also evidence indicating that cleavage of 
pri-miRNA by Drosha can be closely coupled with transcription of the pri-miRNAs from 
either intronic or intergenic miRNA genes [31].   
 
Accumulating evidence suggests that processing of pri-miRNA by Drosha itself is 
insufficient and often erroneous, since imprecise cleavage occurred by the recombinant 
Drosha protein [32].  Inaccuracy of pri-miRNA cleavage will result in production of pre-
miRNAs with altered hairpin secondary structure and identities.  To ensure efficient and 
precise processing of pri-miRNA by Drosha, a number of co-factors are necessarily 
needed.  Indeed, protein fractionation by affinity chromatography revealed that Drosha is 
present in protein complexes with different sizes in vivo [32, 33]. The study performed 
by Gregory et al. showed association of Drosha with 2 different complexes, a large 
complex with ~ 20 proteins and a small complex consisting of Drosha and DiGeorge 
123
  
syndrome critical region 8 (DGCR8) [32].  The association of Drosha with these proteins 
forms microprocessors to ensure the fidelity and activity of Drosha cleavage on pri-
miRNA [32]. DGCR8 is a protein found within the DiGeorge syndrome critical region 
and was revealed to be essential for the processing of pri-miRNA to pre-miRNA by 
Drosha.  At about the same time, Han et al. also identified DGCR8 as a critical player in 
miRNA processing and demonstrated  that the microprocessor complex may be 
composed of multiple DGCR8 and Drosha molecules, possibly creating a dynamic 
processing structure [33]. Because most pri-miRNAs have similar structures typified by a 
terminal loop, a double stranded stem, and single stranded flanking sequences, it was 
speculated that this common structure may be the determining factor that regulates pri-
miRNA cleavage (Fig. 2). There is evidence indicating that both the terminal loop and 
single stranded flanking sequences are important for processing efficiency [4, 34, 35].  
An in-depth look at the molecular mechanisms controlling the binding of pri-miRNAs by 
the microprocessor complex suggests that DGCR8 is responsible for the binding of the 
complex to the pri-miRNA stem-loop. DGCR8 recognizes both the single stranded flanks 
and the double stranded stem, and then acts as a ruler guiding Drosha to cleave the 
molecule in the correct place, 11 base pairs up the stem from the ssRNA-dsRNA junction 
(Fig. 2) [36]. 
 
In addition to DGCR8, other well-characterized proteins in the microprocessor 
which facilitate the activity of Drosha include two DEAD-box RNA helicases p68 and 
p72 [32, 37].  Both p68 and p72 are originally identified as ATP-dependent RNA 
helicases important for pre-mRNA and pre-rRNA splicing by association with 
spliceosome complexes [38].  Genetic disruption of either p68 or p72 in mice is lethal.  
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Surveying miRNA expression profiling using embryo fibroblast cells (MEF) suggests 
about 35% reduction of pre-miRNA and mature miRNA expression in p68 or p72 gene 
knockout MEFs relative to the wild type MEFs.  Intriguingly, the level of pri-miRNAs is 
comparable between the knockout MEFs and the wild-type MEFs, indicating contribution 
of p68 or p72 to the Drosha-mediated pri-miRNA processing [39].  Direct evidence of 
p68 and p72 in pri-miRNA processing was provided by demonstrating their interaction 
with the Drosha and DGCR8 proteins in an immunoprecipitation-mass spectromic 
analysis [32, 37]. 
 
Regulation of the microprocessor by SMADS: 
The first evidence showing additional proteins binding to and modulating the 
function of the Drosha complex was provided by Davis et al. in 2008 [40]. Through 
studying which miRNAs might play a role in the phenotypic changes of the vascular 
smooth muscle cells in response to TGF-β signaling, they found that miR-21 and miR-
199a were induced by BMP4 and TGF-β stimulation. Further studies indicate that such 
an induction occurred at the post-transcriptional level because BMP4 or TGF-β rapidly 
induces pre-miR-21 and mature miR-21 but not pri-miR-21.  Indeed, the expression of 
pri-miR-21 stayed stable following the activation of the TGF-β signaling.  The induction 
of pre-miR-21 and miR-21 by BMP4 or TGF-β was blocked in the cells when expression 
of SMAD proteins was repressed by siRNA knock-down.  Previous studies suggest that 
the MH2 domain on the carboxyl-terminus of SMAD proteins is capable of binding to 
p68, the RNA helicase associated with the Drosha complex [41].  This conclusion was 
supported by Davis et al. [40] who demonstrated direct interaction of p68 with SMAD1, 
3, and 5 in a GST-pull down experiment.  The interaction of Drosha with the p68/SMAD 
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complex occurred only under conditions where the miRNA transcripts were intact.  
Furthermore, RNA co-immunoprecipitation confirmed the specific regulation of SMADs 
on the microprocessors of miR-21 and miR-199a, but not miR-214, in response to BMP4 
or TGF-β (Fig. 2).  
 
Activation of SMAD proteins by TGF-β has long been assumed as a mechanism 
for inducing epithelial to mesenchymal transition (EMT) and overall cancer cell growth. 
Adding to this role, the above study demonstrates an additional function of TGF-β being 
able to increase the expression of miRNAs 21 and 199a.  MiR-21 is the most commonly 
over-expressed miRNA in cancers [42]. Over-expression of miR-21 has been reported in 
more than 15 different malignancies [43].  The oncogenic potential of miR-21 is largely 
attributed to its involvement in several intracellular signaling pathways, including the 
activation of AKT [44] and antagonizing the expression of the pro-apoptotic protein 
PDCD4 [45]. Expression of miR-199a has also been associated with cancers. One study 
suggests that leukemias with higher expression of miR-199a exhibit a worse prognosis 
[46].  Several other studies, however, show that a loss in expression of miR-199a, 
enhanced tumor progression by an enhancement of IKKβ expression and its induced 
inflammatory and tumorigenic signals in ovarian cancer [47].  
 
TGF-β and SMAD4 have also been recognized as key players in inducing 
transcription of miR-155 and miR-214, two other oncogenic miRNAs [48]. Elevated 
miR-155 represses RhoA protein expression, reduces the ability of epithelial cells to form 
tight junctions, and enhances a tumors’ ability of metastasis [48].  In ovarian cancer, 
miR-214 is overexpressed, leading to a sustained activation of the Akt kinases by down-
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regulation of PTEN, a negative regulator of Akt signaling.  Decrease in PTEN 
expression, thus, causes an aberrant activation of Akt and resistance of the tumor cells to 
chemotherapy, such as cisplatin treatment [49].  
 
The above reports detailing regulation of Drosha processing by SMADs in 
response to TGF-β signaling are of particular interest.  This modulation appears to be 
specific to a subset of miRNAs, and it will be important to determine what other miRNAs 
are regulated by this same mechanism and what molecular events govern such regulation. 
It appears that the binding of SMAD proteins to the Drosha microprocessor stabilizes the 
formation of the complex on a specific set of pri-miRNAs.  Accordingly, it will be 
important to determine the downstream targets of these miRNAs and whether regulation 
of miRNA processing is a major mechanism of TGF-β in cell transformation and 
carcinogenesis.  
 
p53 and miRNA processing 
The tumor suppressor p53 is perhaps the most intensively studied protein in cell 
biology and cancer.  As a transcription factor, the tumor suppressor function of p53 is 
achieved largely by transcriptional up-regulation of a number of pro-apoptotic proteins. A 
recent study by Suzuki and colleagues demonstrates a novel mechanism of p53 in tumor 
suppression by regulating miRNA biogenesis at the level of Drosha microprocessor [50].  
The interaction of p53 with p68, a protein associated with the Drosha microprocessor, has 
been previously demonstrated [51].  In the latest study, it was noted that p53 is capable of 
interacting with p68 and p72, both of which are Drosha-associated RNA helicases (Fig. 
2).  Using doxorubicin as a DNA damaging agent and p53  inducer in human colon 
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cancer cell line HCT116, the expression of a subset of miRNAs was up-regulated.  These 
miRNAs include miR-15a, miR-16-1, miR-23a, miR-26a, miR-103, miR-143, miR-145, 
miR-203, as well as miR-34a that had previously been determined to be induced by p53 
[52]. Upon examination of the expression levels of pri-, pre- and mature miRNAs for 
each of the miRNAs regulated by doxorubicin, as expected, all species of miR-34a, a 
transcriptional target of p53, were upregulated.  Interestingly, several other miRNAs 
showed increases of pre- and mature miRNA species, but not the pri-miRNA transcripts, 
suggesting that the regulation of p53 for some of these miRNAs is independent of 
transcription.  Furthermore, cancer-associated p53 mutants fail to bind p68 or induce 
miRNA processing.  Overexpression of each of these p53-regulated miRNAs 
substantially decreased the rate of cell proliferation.  Taken together, these data clearly 
indicate that mutation of p53 in cancers hinders the maturation of several miRNAs 
important for tumor suppression and leads to an increased tumorigenic potential.  
 
 The involvement of p53 in miRNA biogenesis post-transcriptionally provides 
evidence of a global control mechanism for subsets of miRNAs involved in similar 
cellular functions.  The p53 transcriptional target, miR-34a, was shown to repress tumor 
progression in multiple cancers [53-55] and has recently been found to target c-met and 
Notch1/Notch2 in glioblastomas [56].  Interestingly, expression of miR-15a and miR-16-
1 is often reduced in tumors.  Both miR-15a and miR-16-1 have been shown to target the 
anti-apoptotic protein, BCL2 [57, 58].  This cluster of miRNAs is also observed to be 
able to target additional proteins such as Cyclin D1 and WNT3A, which promote 
tumorigenesis [59]. Decreased expression of miR-143 and miR-145 has been strongly 
linked to colon cancer [60-62]. MiR-143 has been shown to target KRAS [63] and DNA 
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methyltransferase 3A [62].  In breast cancer, loss of miR-145 resulted in an elevation of 
rhotekin (RTKN), a scaffolding protein for Rho-GTP that is involved in cell proliferation 
[64]. 
 
 The involvement of p53 in miRNA biogenesis was unexpected.  The capability of 
p53 to regulate miRNA expression obviously strengthens its tumor suppressor function 
further.  The questions that remain unanswered are why association of p53 with the 
Drosha microprocessor only regulates a selected subset of miRNAs but not others and 
how does p53 alter the recognition and processing dynamics of the Drosha complex 
toward the pri-miRNA repertoire.  Nevertheless, the discovery of p53 regulation on 
miRNA processing confirms that p53 is  a powerful suppressor for cancer formation.  
Loss of p53 as observed in multiple cancers, therefore, will not only weaken the 
checkpoint mechanisms of the cells but also impair the generation of those tumor 
suppressor-like miRNAs. 
 
 ARS2 regulation of miRNA processing 
Arsenic Resistance protein 2 (Ars2) is a protein whose expression is strongly 
linked to the proliferation of cells especially during embryonic development [65]. 
Recently two studies have been published linking Ars2 expression to miRNA processing. 
The study by Gruber et al. [66] show that in addition to its role in cell proliferation, 
depletion of Ars2 in mammalian cells repressed miRNA-mediated silencing of reporter 
genes.  After siRNA knockdown of Ars2, the ability of let-7 to repress the expression of a 
luciferase reporter construct was significantly reduced. Addition of the let-7 duplex RNA 
was able to reverse the loss of reporter repression, indicating that Ars2 does not function 
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down-stream of Drosha processing.  Immunoprecipitation of Drosha proteins was able to 
pull down Ars2, while the same experiment with Dicer did not. This further indicates that 
repression of miRNA function occurs at the Drosha processing step (Fig. 2).  Previous 
research performed on SERRATE, a plant homolog of Ars2, indicates that Ars2 was 
responsible for regulating the appropriate processing of miRNA by Drosha [67].  
However, Gruber et al. found that Ars2 was not required for processing of all miRNAs, 
but only for a subset containing let-7 and miR-21.  After screening for factors important 
in antiviral defense in Drosophila, Sabin et al. simultaneously observed a similar activity 
of Ars2 in miRNA processing in Drosophila with viral infection [68]. They identified 
that Ars2 is critical for intrinsic antiviral defense in Drosophila.  Loss of Ars2 leads to a 
pronounced increase in viral replication of several RNA viruses in both cell culture and 
adult flies. Using an over-expression strategy, Sabin et al. [68] also demonstrate that Ars2 
was capable of binding to Pasha, also known as DGCR8 in mammals, the double-
stranded RNA binding partner of Drosha.  Additional experiments implied interaction 
between Ars2 and the nuclear cap-binding complex (CBC) that recognizes and binds to 
the 5’-cap of pri-miRNA transcripts.  Based on all of these observations, two 
nonexclusive models for the role of Ars2 in miRNA processing were proposed. The first 
is the so-called bridging model, in which both Ars2 and CBC bind pri-miRNA transcripts 
followed by recruitment of the Drosha microprocessor by Ars2.  In the second model, 
Ars2 acts as a cofactor for Drosha’s enzymatic activity by enhancing the overall 
processing activity and fidelity of the microprocessor [68]. 
 
 The discovery of Ars2 in miRNA processing further emphasizes the point that 
miRNA biogenesis and activity are highly regulated processes involving multiple 
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proteins at various stages. Although Ars2 is a protein which has not been extensively 
studied, early reports indicating its contributions to cell proliferation and more recent 
studies showing its role in miRNA processing suggest that Ars2 may be a potential target 
for therapeutic intervention in various disease states including cancer.   
 
 Cell-to-cell contact affects miRNA processing: 
The regulation of microRNA processing has been found to be affected by the 
confluence of the culture or the intensity of cell-to-cell contacts.  Hwang et al. found that 
as cultures reach confluence, the expression of most of the miRNAs that they studied also 
increased [69]. They were able to show that this effect occurred across multiple cell lines 
and was typified by an accumulation of pre- and mature miRNA.  This change in miRNA 
levels appears to be independent of the status of cell proliferation, conditions of the cell 
culture media, or the density of the cells in culture.  This indicates that an increase in cell-
to-cell contacts was the impetus for the increase in miRNA processing.  The authors 
further determined that the abundance of pri-miRNA transcript was not increased by the 
status of cell confluence with the interesting exception of miR-34a. Such information 
along with additional experiments indicated that this regulation was caused by an 
increase in efficiency of the Drosha microprocessor as well as formation of mature 
miRISC complexes at the Dicer processing step [69]. 
 
In light of the study discussed earlier indicating the role of p53 in Drosha 
processing, it is very likely that this regulation could be due to p53 activity. Along with 
the non-transcriptional induction of miR-15a, miR-16, miR-26a, and miR-145, the 
observation that miR-34a was the only transcriptionally regulated miRNA in both studies 
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is the key to linking these two studies together.  Furthermore, p53 has been implicated as 
an important mediator for the density-dependant growth inhibition of cells.  One study 
shows that inhibition of p53 led to the loss of density-dependent growth inhibition, 
leading to increased cell density and decreased apoptosis. While no increase of p53 
expression was observed, basal levels were sufficient to cause growth arrest [70]. The 
studies by Suzuki et al. and Hwang et al. may, at least in part, be able to explain how p53 
can cause density-dependent growth inhibition. While most of the miRNAs observed to 
be up regulated by Hwang et al. are involved in growth inhibition, some  are strongly 
associated with proliferation and tumorigenesis, like miR-21. This may indicate that 
additional proteins are involved in the effect of cell confluence- or cell-to-cell interaction-
mediated miRNA processing. It would  be of interest to determine if the effect seen on 
processing efficiency by Dicer and miRISC formation is also due to p53 activity or to 
additional modulators of miRNA processing. 
 
 Inhibition of miRNA biogenesis by estrogen 
Estrogen hormones are well known regulators for transcription and post-
transcriptional events of a number of genes through binding to their specific nuclear 
estrogen receptors (ERs), ERα or ERβ.  Although both receptors exhibit a similar affinity 
toward estrogen, a distinction in tissue distribution between ERα and ERβ has long been 
recognized.  ERα is mainly found in endometrium, breast cancer cells, ovarian stroma 
cells, and in the hypothalamus, whereas ERβ appears to be ubiquitously expressed.  By 
using embryos derived from female mice with a genetic deficiency of ERα, a recent 
study by Yamagata et al.[71] reported an upregulation of some miRNAs.  Conversely, 
such an upregulation was reversed by estrogen (E2) treatment, suggesting that estrogen 
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and its receptor signaling are negative regulators for certain miRNAs, including miR-16, 
miR-26a, miR-29a, miR-125a, miR-143, miR-145, miR-195, etc..  Further studies 
indicate that the negative regulation of ERα on these miRNAs occurred at the level of 
pri-miRNA processing, rather than transcription.  A direct physical association of the E2-
bound ERα with Drosha microprocessor components, p68 and p72, was noted in an 
immunoprecipitation assay.  The regulation of ERα on miRNA biogenesis was also 
validated in human cells.  Collectively, these data suggest that E2-ERα signaling is 
antagonistic for miRNA processing, possibly through direct interaction between ERα and 
p68/p72, leading to dissociation of the Drosha microprocessor from a subset of pri-
miRNAs. 
 
The evidence showing inhibitory roles of ERα on the biogenesis of a select subset 
of miRNAs provides a new explanation for the molecular mechanisms of the ERα 
positive breast cancers.  Due to its negative regulation on some of these tumor 
suppressor-like miRNAs, including miR-16 and miR-26a, ERα can amplify the 
tumorigenic signals from VEGF [71], EZH2 [72] and some oncogenes that are targeted 
by miR-16 or miR-26a in breast epithelial cells.  Thus, there is strong indication for 
pursuing an ERα-based therapeutic approach.  First, suppression of the ERα signaling by 
selective ERα modulators, such as tamoxifen, can inactivate transcriptional regulation of 
ERα on some growth factors important for the transformation of the cells.  Second, 
blocking ERα signaling will enhance the tumor suppressive potential of the cells by 
promoting the biogenesis of those tumor suppressor-like miRNAs, which limit the growth 




Summary and Conclusions: 
An underlying theme in the regulation of miRNA biogenesis at the Drosha 
processing step seems to be that regulatory proteins selectively alter the expression of 
certain subsets of miRNAs. This is not entirely surprising, as the cellular functions of 
miRNAs are diverse, and global up-regulation or down-regulation of all miRNAs might 
cause havoc on cellular systems. The miRNA subsets whose expression are altered by the 
regulatory proteins discussed above seem to be in line with the traditionally accepted 
roles for those proteins.  As more and more regulatory proteins are discovered for all 
steps of miRNA production and processing, it is most likely that this theme will be 
extended. The activation of Smad proteins is associated with cell growth and 
transformation, and the miRNAs that are regulated by Smads are associated with similar 
effects. On the other hand, expression and activation of p53 is a well known mechanism 
of cell cycle arrest and apoptosis, and its downstream miRNAs can be effectors of the 
same pathways. While Ars2 is not a very well-studied protein and its detailed function 
remains to be fully elucidated, recent research shows that it is involved in cell 
proliferation. Likewise, the miRNAs that Ars2 has been shown to regulate are involved in 
similar cellular functions. Additional research should be done to delineate exactly which 
miRNAs are in each regulated subset. This information would be useful for determining 
if therapeutic intervention of proteins, such as Ars2, would be a fruitful endeavor.  
 
 One exception to the theme is the observed activation of miRNA biogenesis by 
cell-to-cell contacts. This effect appears to be global (with few exceptions), including the 
expression of miRNA that have historically opposite effects. Cellular signaling that 
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occurs during quiescence is highly complex, and the study by Hwang et al. now places 
miRNA expression into the mix [69]. 
 
 As the study of miRNA biogenesis continues, it is apparent that more proteins 
will be discovered to play regulatory roles at various processing steps. It will be 
important to determine whether or not these proteins or processing pathways are 
legitimate  targets for therapeutic intervention. It is becoming increasingly clear that 
subsets of miRNA play important roles in multiple disease states. If there are master 
regulators of expression of these subsets, they could be potential targets for intervention 
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Figure 1.   MicroRNA (miRNA) production and processing. The pri-miRNA transcript is 
transcribed by RNA polymerase II. The stem loop structure is cleaved off by the 
microprocessor to generate pre-miRNA. The pre-miRNA is exported to the cytoplasm by 
exportin5 in a ran-GTP dependent manner. Once in the cytoplasm, the pre-miRNA is 
processed by Dicer creating a single stranded mature miRNA. This mature miRNA is 
bound by the RISC complex, guiding it to the 3’UTR of target mRNAs, leading to 







Figure 2.  Modulation of microprocessor function by SMAD, p53 and Ars2 in response 
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